{ "version": "2.2", "instance": { "f6k_022824.htm exh_991.htm": { "nsprefix": "ptgef", "nsuri": "http://portagebiotech.com/20231231", "dts": { "inline": { "local": [ "exh_991.htm", "f6k_022824.htm" ] }, "schema": { "local": [ "ptgef-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "ptgef-20231231_cal.xml" ] }, "definitionLink": { "local": [ "ptgef-20231231_def.xml" ] }, "labelLink": { "local": [ "ptgef-20231231_lab.xml" ] }, "presentationLink": { "local": [ "ptgef-20231231_pre.xml" ] } }, "keyStandard": 162, "keyCustom": 285, "axisStandard": 16, "axisCustom": 1, "memberStandard": 8, "memberCustom": 55, "hidden": { "total": 252, "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 63, "http://portagebiotech.com/20231231": 184, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 212, "entityCount": 1, "segmentCount": 69, "elementCount": 648, "unitCount": 6, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 471, "http://xbrl.sec.gov/dei/2023": 15 }, "report": { "R1": { "role": "http://portagebiotech.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "f6k_022824.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "f6k_022824.htm", "first": true, "unique": true } }, "R2": { "role": "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition", "longName": "00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)", "shortName": "Condensed Consolidated Interim Statements of Financial Position (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "ifrs-full:TradeAndOtherCurrentReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "unique": true } }, "R3": { "role": "http://portagebiotech.com/role/InterimStatementsOfFinancialPositionParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Interim Statements of Financial Position (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:DeferredCommitmentFeeNetOfAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:DeferredCommitmentFeeNetOfAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R4": { "role": "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss", "longName": "00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)", "shortName": "Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R5": { "role": "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLossParenthetical", "longName": "00000005 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "ifrs-full:BasicEarningsLossPerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "longName": "00000006 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2022-03-31_ifrs-full_IssuedCapitalMember", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-03-31_ifrs-full_IssuedCapitalMember", "name": "ifrs-full:Equity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R7": { "role": "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "longName": "00000007 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Interim Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:LossIncomeOnFairValueOfWarrantLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "unique": true } }, "R8": { "role": "http://portagebiotech.com/role/NatureOfOperations", "longName": "00000008 - Disclosure - NATURE OF OPERATIONS", "shortName": "NATURE OF OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:NatureOfOperationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:NatureOfOperationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R9": { "role": "http://portagebiotech.com/role/GoingConcern", "longName": "00000009 - Disclosure - GOING CONCERN", "shortName": "GOING CONCERN", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfGoingConcernExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfGoingConcernExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R10": { "role": "http://portagebiotech.com/role/BasisOfPresentation", "longName": "00000010 - Disclosure - BASIS OF PRESENTATION", "shortName": "BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R11": { "role": "http://portagebiotech.com/role/SignificantAccountingPolicies", "longName": "00000011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R12": { "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables", "longName": "00000012 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES", "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R13": { "role": "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivable", "longName": "00000013 - Disclosure - INVESTMENT IN ASSOCIATE AND CONVERTIBLE NOTE RECEIVABLE", "shortName": "INVESTMENT IN ASSOCIATE AND CONVERTIBLE NOTE RECEIVABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:InvestmentInAssociateAndConvertibleNoteReceivableDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:InvestmentInAssociateAndConvertibleNoteReceivableDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R14": { "role": "http://portagebiotech.com/role/InvestmentInPublicCompany", "longName": "00000014 - Disclosure - INVESTMENT IN PUBLIC COMPANY", "shortName": "INVESTMENT IN PUBLIC COMPANY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfInvestmentInPublicCompaniesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfInvestmentInPublicCompaniesExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R15": { "role": "http://portagebiotech.com/role/Lease", "longName": "00000015 - Disclosure - LEASE", "shortName": "LEASE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R16": { "role": "http://portagebiotech.com/role/AcquisitionOfTarus", "longName": "00000016 - Disclosure - ACQUISITION OF TARUS", "shortName": "ACQUISITION OF TARUS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:AcquisitionsOfTarusExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:AcquisitionsOfTarusExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R17": { "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability", "longName": "00000017 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY", "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiabilityExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiabilityExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R18": { "role": "http://portagebiotech.com/role/WarrantLiability", "longName": "00000018 - Disclosure - WARRANT LIABILITY", "shortName": "WARRANT LIABILITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:WarrantLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:WarrantLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R19": { "role": "http://portagebiotech.com/role/IncomeTaxes", "longName": "00000019 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R20": { "role": "http://portagebiotech.com/role/CapitalStock", "longName": "00000020 - Disclosure - CAPITAL STOCK", "shortName": "CAPITAL STOCK", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfCapitalStockExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfCapitalStockExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R21": { "role": "http://portagebiotech.com/role/StockOptionReserve", "longName": "00000021 - Disclosure - STOCK OPTION RESERVE", "shortName": "STOCK OPTION RESERVE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R22": { "role": "http://portagebiotech.com/role/LossPerShare", "longName": "00000022 - Disclosure - (LOSS) PER SHARE", "shortName": "(LOSS) PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R23": { "role": "http://portagebiotech.com/role/CommitmentsAndContingentLiabilities", "longName": "00000023 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R24": { "role": "http://portagebiotech.com/role/RelatedPartyTransactions", "longName": "00000024 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R25": { "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement", "longName": "00000025 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT", "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfFinancialInstrumentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfFinancialInstrumentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R26": { "role": "http://portagebiotech.com/role/CapitalDisclosures", "longName": "00000026 - Disclosure - CAPITAL DISCLOSURES", "shortName": "CAPITAL DISCLOSURES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R27": { "role": "http://portagebiotech.com/role/Non-controllingInterest", "longName": "00000027 - Disclosure - NON-CONTROLLING INTEREST", "shortName": "NON-CONTROLLING INTEREST", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R28": { "role": "http://portagebiotech.com/role/EventsAfterBalanceSheetDate", "longName": "00000028 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE", "shortName": "EVENTS AFTER THE BALANCE SHEET DATE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfEventAfterBalanceSheetDateExpanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfEventAfterBalanceSheetDateExpanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R29": { "role": "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies", "longName": "00000029 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "29", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R30": { "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables", "longName": "00000030 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)", "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherAssetsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherAssetsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R31": { "role": "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableTables", "longName": "00000031 - Disclosure - INVESTMENT IN ASSOCIATE AND CONVERTIBLE NOTE RECEIVABLE (Tables)", "shortName": "INVESTMENT IN ASSOCIATE AND CONVERTIBLE NOTE RECEIVABLE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfInvestmentAssociatetableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:InvestmentInAssociateAndConvertibleNoteReceivableDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfInvestmentAssociatetableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:InvestmentInAssociateAndConvertibleNoteReceivableDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R32": { "role": "http://portagebiotech.com/role/LeaseTables", "longName": "00000032 - Disclosure - LEASE (Tables)", "shortName": "LEASE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R33": { "role": "http://portagebiotech.com/role/AcquisitionOfTarusTables", "longName": "00000033 - Disclosure - ACQUISITION OF TARUS (Tables)", "shortName": "ACQUISITION OF TARUS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R34": { "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables", "longName": "00000034 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)", "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiabilityExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiabilityExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R35": { "role": "http://portagebiotech.com/role/WarrantLiabilityTables", "longName": "00000035 - Disclosure - WARRANT LIABILITY (Tables)", "shortName": "WARRANT LIABILITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ScheduleOfWarrantLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ScheduleOfWarrantLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R36": { "role": "http://portagebiotech.com/role/IncomeTaxesTables", "longName": "00000036 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R37": { "role": "http://portagebiotech.com/role/CapitalStockTables", "longName": "00000037 - Disclosure - CAPITAL STOCK (Tables)", "shortName": "CAPITAL STOCK (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:DisclosureOfCapitalStockExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:DisclosureOfCapitalStockExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R38": { "role": "http://portagebiotech.com/role/StockOptionReserveTables", "longName": "00000038 - Disclosure - STOCK OPTION RESERVE (Tables)", "shortName": "STOCK OPTION RESERVE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfTermsStockOptionReserveExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfTermsStockOptionReserveExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R39": { "role": "http://portagebiotech.com/role/LossPerShareTables", "longName": "00000039 - Disclosure - (LOSS) PER SHARE (Tables)", "shortName": "(LOSS) PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ScheduleOfEarningsPerShareTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:EarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ScheduleOfEarningsPerShareTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:EarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R40": { "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables", "longName": "00000040 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)", "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:DisclosureOfFinancialInstrumentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ptgef:DisclosureOfFinancialInstrumentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R41": { "role": "http://portagebiotech.com/role/Non-controllingInterestTables", "longName": "00000041 - Disclosure - NON-CONTROLLING INTEREST (Tables)", "shortName": "NON-CONTROLLING INTEREST (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R42": { "role": "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative", "longName": "00000042 - Disclosure - NATURE OF OPERATIONS (Details Narrative)", "shortName": "NATURE OF OPERATIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "From2021-09-012021-09-30", "name": "ptgef:PercentageOfOutstandingShares", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ptgef:NatureOfOperationsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2018-08-13_custom_SalvaRxGroupPlcMember", "name": "ifrs-full:PercentageOfVotingEquityInterestsAcquired", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ptgef:NatureOfOperationsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "unique": true } }, "R43": { "role": "http://portagebiotech.com/role/GoingConcernDetailsNarrative", "longName": "00000043 - Disclosure - GOING CONCERN (Details Narrative)", "shortName": "GOING CONCERN (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ifrs-full:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGoingConcernExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "ifrs-full:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGoingConcernExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R44": { "role": "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "longName": "00000044 - Disclosure - BASIS OF PRESENTATION (Details Narrative)", "shortName": "BASIS OF PRESENTATION (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2021-09-012021-09-30", "name": "ptgef:PercentageOfOutstandingShares", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ptgef:NatureOfOperationsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-04-012023-12-31_custom_SaugatuckMember", "name": "ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "unique": true } }, "R45": { "role": "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative", "longName": "00000045 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DescriptionOfNatureOfNonadjustingEventAfterReportingPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:DescriptionOfNatureOfNonadjustingEventAfterReportingPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R46": { "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails", "longName": "00000046 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)", "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ifrs-full:CurrentReceivablesFromSaleOfProperties", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock", "ifrs-full:DisclosureOfOtherAssetsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "ifrs-full:CurrentReceivablesFromSaleOfProperties", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock", "ifrs-full:DisclosureOfOtherAssetsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R47": { "role": "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails", "longName": "00000047 - Disclosure - INVESTMENT IN ASSOCIATE AND CONVERTIBLE NOTE RECEIVABLE (Details)", "shortName": "INVESTMENT IN ASSOCIATE AND CONVERTIBLE NOTE RECEIVABLE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "From2023-04-012023-12-31_custom_StimunitySAMember", "name": "ifrs-full:NameOfAssociate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "ptgef:DisclosureOfInvestmentAssociatetableTextBlock", "ptgef:InvestmentInAssociateAndConvertibleNoteReceivableDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-012023-12-31_custom_StimunitySAMember", "name": "ifrs-full:NameOfAssociate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "ptgef:DisclosureOfInvestmentAssociatetableTextBlock", "ptgef:InvestmentInAssociateAndConvertibleNoteReceivableDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R48": { "role": "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails1", "longName": "00000048 - Disclosure - INVESTMENT IN ASSOCIATE AND CONVERTIBLE NOTE RECEIVABLE (Details 1)", "shortName": "INVESTMENT IN ASSOCIATE AND CONVERTIBLE NOTE RECEIVABLE (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2023-03-31", "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutInvestmentPropertyExplanatory", "ptgef:InvestmentInAssociateAndConvertibleNoteReceivableDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:UnrecognisedShareOfLossesOfAssociate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutInvestmentPropertyExplanatory", "ptgef:InvestmentInAssociateAndConvertibleNoteReceivableDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "unique": true } }, "R49": { "role": "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetailsNarrative", "longName": "00000049 - Disclosure - INVESTMENT IN ASSOCIATE AND CONVERTIBLE NOTE RECEIVABLE (Details Narrative)", "shortName": "INVESTMENT IN ASSOCIATE AND CONVERTIBLE NOTE RECEIVABLE (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "From2023-07-122023-07-13", "name": "ptgef:ConvertibleNoteDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ptgef:InvestmentInAssociateAndConvertibleNoteReceivableDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-122023-07-13", "name": "ptgef:ConvertibleNoteDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ptgef:InvestmentInAssociateAndConvertibleNoteReceivableDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R50": { "role": "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative", "longName": "00000050 - Disclosure - INVESTMENT IN PUBLIC COMPANY (Details Narrative)", "shortName": "INVESTMENT IN PUBLIC COMPANY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "AsOf2023-04-30", "name": "ptgef:ReverseStockSplitHoldingShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ptgef:DisclosureOfInvestmentInPublicCompaniesExplanatoryTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-04-30", "name": "ptgef:ReverseStockSplitHoldingShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ptgef:DisclosureOfInvestmentInPublicCompaniesExplanatoryTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R51": { "role": "http://portagebiotech.com/role/LeaseDetails", "longName": "00000051 - Disclosure - LEASE (Details)", "shortName": "LEASE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:LesseeOperatingLeaseLiabilityPaymentDueNextRollingTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:LesseeOperatingLeaseLiabilityPaymentDueNextRollingTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R52": { "role": "http://portagebiotech.com/role/LeaseDetailsNarrative", "longName": "00000052 - Disclosure - LEASE (Details Narrative)", "shortName": "LEASE (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ifrs-full:LongtermDeposits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "ifrs-full:LongtermDeposits", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R53": { "role": "http://portagebiotech.com/role/AcquisitionOfTarusDetails", "longName": "00000053 - Disclosure - ACQUISITION OF TARUS (Details)", "shortName": "ACQUISITION OF TARUS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R54": { "role": "http://portagebiotech.com/role/AcquisitionOfTarusDetails1", "longName": "00000054 - Disclosure - ACQUISITION OF TARUS (Details 1)", "shortName": "ACQUISITION OF TARUS (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "From2022-04-012022-12-31", "name": "ifrs-full:ProfitLossFromContinuingOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfProformaInformationTableTextBlock", "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-04-012022-12-31", "name": "ifrs-full:ProfitLossFromContinuingOperations", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfProformaInformationTableTextBlock", "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R55": { "role": "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative", "longName": "00000055 - Disclosure - ACQUISITION OF TARUS (Details Narrative)", "shortName": "ACQUISITION OF TARUS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:NumberOfShareIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:NumberOfShareIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R56": { "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "longName": "00000056 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)", "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:InprocessResearchAndDevelopment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:DeferredTaxesLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock", "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiabilityExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "unique": true } }, "R57": { "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative", "longName": "00000057 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)", "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "ifrs-full:ProvisionUsedOtherProvisions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiabilityExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "ifrs-full:ProvisionUsedOtherProvisions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiabilityExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R58": { "role": "http://portagebiotech.com/role/WarrantLiabilityDetails", "longName": "00000058 - Disclosure - WARRANT LIABILITY (Details)", "shortName": "WARRANT LIABILITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ChangeInFairValueOfWarrantLiabilityAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfWarrantLiabilityTableTextBlock", "ptgef:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ChangeInFairValueOfWarrantLiabilityAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfWarrantLiabilityTableTextBlock", "ptgef:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R59": { "role": "http://portagebiotech.com/role/WarrantLiabilityDetails1", "longName": "00000059 - Disclosure - WARRANT LIABILITY (Details 1)", "shortName": "WARRANT LIABILITY (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "AsOf2023-10-03_custom_SeriesBWarrantsMember", "name": "ptgef:ExercisePriceFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "b", "span", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "ptgef:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-03_custom_SeriesBWarrantsMember", "name": "ptgef:ExercisePriceFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "b", "span", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "ptgef:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R60": { "role": "http://portagebiotech.com/role/WarrantLiabilityDetails2", "longName": "00000060 - Disclosure - WARRANT LIABILITY (Details 2)", "shortName": "WARRANT LIABILITY (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "AsOf2023-10-03_custom_SeriesCWarrantsMember", "name": "ptgef:ExercisePriceFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "b", "span", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "ptgef:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-03_custom_SeriesCWarrantsMember", "name": "ptgef:ExercisePriceFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "b", "span", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "ptgef:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R61": { "role": "http://portagebiotech.com/role/WarrantLiabilityDetails3", "longName": "00000061 - Disclosure - WARRANT LIABILITY (Details 3)", "shortName": "WARRANT LIABILITY (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "AsOf2023-10-03_custom_PlacementAgentWarrantsMember", "name": "ptgef:ExercisePriceFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "b", "span", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "ptgef:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-03_custom_PlacementAgentWarrantsMember", "name": "ptgef:ExercisePriceFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "b", "span", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "ptgef:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R62": { "role": "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative", "longName": "00000062 - Disclosure - WARRANT LIABILITY (Details Narrative)", "shortName": "WARRANT LIABILITY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ExercisableAggregateOrdinaryShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ptgef:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ExercisableAggregateOrdinaryShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ptgef:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R63": { "role": "http://portagebiotech.com/role/IncomeTaxesDetails", "longName": "00000063 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:CurrentFederalIncomeTaxBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:CurrentFederalIncomeTaxBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R64": { "role": "http://portagebiotech.com/role/IncomeTaxesDetails1", "longName": "00000064 - Disclosure - INCOME TAXES (Details 1)", "shortName": "INCOME TAXES (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R65": { "role": "http://portagebiotech.com/role/IncomeTaxesDetails2", "longName": "00000065 - Disclosure - INCOME TAXES (Details 2)", "shortName": "INCOME TAXES (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:AccountingProfit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfIncomeTaxTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:AccountingProfit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfIncomeTaxTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R66": { "role": "http://portagebiotech.com/role/IncomeTaxesDetails3", "longName": "00000066 - Disclosure - INCOME TAXES (Details 3)", "shortName": "INCOME TAXES (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:PretaxIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ptgef:ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:PretaxIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ptgef:ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R67": { "role": "http://portagebiotech.com/role/IncomeTaxesDetails4", "longName": "00000067 - Disclosure - INCOME TAXES (Details 4)", "shortName": "INCOME TAXES (Details 4)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:DeferredTaxAssetsNetOperatingLossCarryforward", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfDeferredTaxAssetsTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:DeferredTaxAssetsNetOperatingLossCarryforward", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfDeferredTaxAssetsTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R68": { "role": "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative", "longName": "00000068 - Disclosure - INCOME TAXES (Details Narrative)", "shortName": "INCOME TAXES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:FederalNetOperatingLosses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:FederalNetOperatingLosses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R69": { "role": "http://portagebiotech.com/role/CapitalStockDetails", "longName": "00000069 - Disclosure - CAPITAL STOCK (Details)", "shortName": "CAPITAL STOCK (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "AsOf2023-03-31_ifrs-full_IssuedCapitalMember", "name": "ptgef:CommonStockShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock", "ptgef:DisclosureOfCapitalStockExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-03-31_ifrs-full_IssuedCapitalMember", "name": "ptgef:CommonStockShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock", "ptgef:DisclosureOfCapitalStockExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R70": { "role": "http://portagebiotech.com/role/CapitalStockDetails1", "longName": "00000070 - Disclosure - CAPITAL STOCK (Details 1)", "shortName": "CAPITAL STOCK (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "From2023-10-012023-10-03_custom_SeriesAWarrantsMember", "name": "ifrs-full:ExercisePriceShareOptionsGranted2019", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "b", "span", "td", "tr", "table", "ptgef:DisclosureOfIputsAssociatedFairValueExplanatory", "ptgef:DisclosureOfCapitalStockExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-012023-10-03_custom_SeriesAWarrantsMember", "name": "ifrs-full:ExercisePriceShareOptionsGranted2019", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "b", "span", "td", "tr", "table", "ptgef:DisclosureOfIputsAssociatedFairValueExplanatory", "ptgef:DisclosureOfCapitalStockExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R71": { "role": "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "longName": "00000071 - Disclosure - CAPITAL STOCK (Details Narrative)", "shortName": "CAPITAL STOCK (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:MaximumAggregateOfferingPrice", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ptgef:DisclosureOfCapitalStockExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:MaximumAggregateOfferingPrice", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ptgef:DisclosureOfCapitalStockExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R72": { "role": "http://portagebiotech.com/role/StockOptionReserveDetails", "longName": "00000072 - Disclosure - STOCK OPTION RESERVE (Details)", "shortName": "STOCK OPTION RESERVE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:AdjustmentsForSharebasedPayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-03-31_ifrs-full_NoncontrollingInterestsMember", "name": "ptgef:StockOptionReserve", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfTermsStockOptionReserveExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "unique": true } }, "R73": { "role": "http://portagebiotech.com/role/StockOptionReserveDetails1", "longName": "00000073 - Disclosure - STOCK OPTION RESERVE (Details 1)", "shortName": "STOCK OPTION RESERVE (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "AsOf2023-03-31_custom_PBIAmendedAndRestated2021EquityIncentivePlanMember", "name": "ptgef:NumberOfOutstandingShareOption", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-03-31_custom_PBIAmendedAndRestated2021EquityIncentivePlanMember", "name": "ptgef:NumberOfOutstandingShareOption", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R74": { "role": "http://portagebiotech.com/role/StockOptionReserveDetails2", "longName": "00000074 - Disclosure - STOCK OPTION RESERVE (Details 2)", "shortName": "STOCK OPTION RESERVE (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "From2023-04-012023-12-31_custom_PBIAmendedAndRestated2021EquityIncentivePlanMember", "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-012023-12-31_custom_PBIAmendedAndRestated2021EquityIncentivePlanMember", "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R75": { "role": "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative", "longName": "00000075 - Disclosure - STOCK OPTION RESERVE (Details Narrative)", "shortName": "STOCK OPTION RESERVE (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "From2023-03-272023-03-29", "name": "ptgef:EquityIncentivePlanIncreasedShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-03-272023-03-29", "name": "ptgef:EquityIncentivePlanIncreasedShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R76": { "role": "http://portagebiotech.com/role/LossPerShareDetails", "longName": "00000076 - Disclosure - (LOSS) PER SHARE (Details)", "shortName": "(LOSS) PER SHARE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true }, "uniqueAnchor": null }, "R77": { "role": "http://portagebiotech.com/role/LossPerShareDetails1", "longName": "00000077 - Disclosure - (LOSS) PER SHARE (Details 1)", "shortName": "(LOSS) PER SHARE (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "AsOf2023-12-31_ifrs-full_WarrantsMember", "name": "ptgef:AntidilutiveEffectOnLossPerShare", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock", "ifrs-full:EarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_ifrs-full_WarrantsMember", "name": "ptgef:AntidilutiveEffectOnLossPerShare", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock", "ifrs-full:EarningsPerShareExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R78": { "role": "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "longName": "00000078 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "AsOf2023-03-02", "name": "ptgef:ServiceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-03-02", "name": "ptgef:ServiceCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R79": { "role": "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "00000079 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:PortageOrdinaryShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:PortageOrdinaryShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R80": { "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "longName": "00000080 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)", "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_AmortizedCostMember", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory", "ptgef:DisclosureOfFinancialInstrumentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "unique": true } }, "R81": { "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "longName": "00000081 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)", "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "AsOf2023-03-31", "name": "ptgef:ImpairmentAnalysis", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ptgef:DisclosureOfFinancialInstrumentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ptgef:ReversalsOfImpairmentLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ptgef:DisclosureOfFinancialInstrumentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "unique": true } }, "R82": { "role": "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative", "longName": "00000082 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)", "shortName": "CAPITAL DISCLOSURES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:AccountsPayableAndAccruedLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "ptgef:AccountsPayableAndAccruedLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true, "unique": true } }, "R83": { "role": "http://portagebiotech.com/role/Non-controllingInterestDetails", "longName": "00000083 - Disclosure - NON-CONTROLLING INTEREST (Details)", "shortName": "NON-CONTROLLING INTEREST (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "AsOf2023-03-31", "name": "ifrs-full:NoncontrollingInterests", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-03-31", "name": "ifrs-full:NoncontrollingInterests", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock", "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "unique": true } }, "R84": { "role": "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative", "longName": "00000084 - Disclosure - EVENTS AFTER THE BALANCE SHEET DATE (Details Narrative)", "shortName": "EVENTS AFTER THE BALANCE SHEET DATE (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "From2023-04-01to2023-12-31", "name": "ifrs-full:ProceedsFromIssuingShares", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ptgef:WarrantLiabilityTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-26_ifrs-full_MajorOrdinaryShareTransactionsMember", "name": "ifrs-full:NumberOfSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ptgef:DisclosureOfEventAfterBalanceSheetDateExpanatory", "body", "html" ], "reportCount": 1, "baseRef": "exh_991.htm", "unique": true } } }, "tag": { "ptgef_ATMMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ATMMember", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "A T M [Member]" } } }, "auth_ref": [] }, "ifrs-full_AccountingProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccountingProfit", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "verboseLabel": "Loss on ordinary activities before tax", "label": "Accounting profit" } }, "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r35", "r36" ] }, "ptgef_AccountsPayableAndAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AccountsPayableAndAccruedExpenses", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses" } } }, "auth_ref": [] }, "ptgef_AccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AccountsPayableAndAccruedLiabilities", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "Accounts Payable And Accrued Liabilities" } } }, "auth_ref": [] }, "ptgef_AccountsPayableAndAccruedLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AccountsPayableAndAccruedLiability", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "AccountsPayableAndAccruedLiability" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedOtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive loss" } }, "en": { "role": { "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]" } } }, "auth_ref": [ "r193" ] }, "ptgef_AccumulatedOtherComprehensiveIncomeLossMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AccumulatedOtherComprehensiveIncomeLossMember", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income Loss [Member]" } } }, "auth_ref": [] }, "ptgef_AcquisitionOfIntensityHoldingLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AcquisitionOfIntensityHoldingLimitedMember", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Acquisition Of Intensity Holding Limited [Member]" } } }, "auth_ref": [] }, "ptgef_AcquisitionOfSalvaRxMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AcquisitionOfSalvaRxMember", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Acquisition Of Salva Rx [Member]" } } }, "auth_ref": [] }, "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "lang": { "en-us": { "role": { "label": "Fair value of shares issued" } }, "en": { "role": { "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r127" ] }, "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "lang": { "en-us": { "role": { "label": "Consideration:" } } }, "auth_ref": [] }, "ptgef_AcquisitionsOfTarusExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AcquisitionsOfTarusExplanatory", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarus" ], "lang": { "en-us": { "role": { "label": "ACQUISITION OF TARUS" } } }, "auth_ref": [] }, "ptgef_AcquistionProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AcquistionProfitLoss", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss", "label": "AcquistionProfitLoss" } } }, "auth_ref": [] }, "ptgef_AdditionalAntidilutionShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AdditionalAntidilutionShares", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional antidilution shares" } } }, "auth_ref": [] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLossParenthetical", "http://portagebiotech.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding, diluted", "verboseLabel": "Weighted average number of shares - Diluted" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r58" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other assets" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]" } } }, "auth_ref": [ "r205" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and other receivables", "label": "Adjustments for decrease (increase) in prepaid expenses" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } } }, "auth_ref": [ "r205" ] }, "ifrs-full_AdjustmentsForDeferredTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDeferredTaxExpense", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Total deferred" } }, "en": { "role": { "documentation": "Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]" } } }, "auth_ref": [ "r205" ] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation" } }, "en": { "role": { "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]" } } }, "auth_ref": [ "r204" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]" } } }, "auth_ref": [ "r205" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable and accrued liabilities", "label": "Adjustments for increase (decrease) in trade accounts payable" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r203" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for non-cash items:" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "http://portagebiotech.com/role/StockOptionReserveDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation expense", "label": "Stock based compensation expense" } }, "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r204" ] }, "ifrs-full_AdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdministrativeExpense", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non-accountable expenses", "verboseLabel": "Clearing fees" } }, "en": { "role": { "documentation": "The amount of expenses that the entity classifies as being administrative." } } }, "auth_ref": [ "r31", "r45", "r148" ] }, "ptgef_AggregateGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AggregateGrossProceeds", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate gross proceeds" } } }, "auth_ref": [] }, "ptgef_AggregateGrossProceedsIncrease": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AggregateGrossProceedsIncrease", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate gross proceeds increase" } } }, "auth_ref": [] }, "ptgef_AggregateValue": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AggregateValue", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate value" } } }, "auth_ref": [] }, "ifrs-full_AggregatedMeasurementMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AggregatedMeasurementMember", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "auth_ref": [ "r67", "r72", "r103" ] }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AllLevelsOfFairValueHierarchyMember", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r40", "r104" ] }, "ptgef_AmendedAndRestated2021EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AmendedAndRestated2021EquityIncentivePlanMember", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amended And Restated 2021 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ptgef_AmortizationOfDeferredCommitmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AmortizationOfDeferredCommitmentFee", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amortization of deferred commitment fee" } } }, "auth_ref": [] }, "ptgef_AmortizedCostMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AmortizedCostMember", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Amortized Cost [Member]" } } }, "auth_ref": [] }, "ptgef_AnnualBonusTargetsRangingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AnnualBonusTargetsRangingPercentage", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual bonus targets ranging percentage" } } }, "auth_ref": [] }, "ptgef_AnnualFeesdescription": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AnnualFeesdescription", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual fees description" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r184" ] }, "ptgef_AntidilutiveEffectOnLossPerShare": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "AntidilutiveEffectOnLossPerShare", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails1" ], "lang": { "en-us": { "role": { "label": "Anti-dilutive effect on loss per share" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Statutory U.K. income tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r36" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets [Default Label]" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r15", "r103", "r104", "r105", "r140", "r143" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets", "verboseLabel": "Assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r184" ] }, "ptgef_BVIMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "BVIMember", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "label": "B V I [Member]" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLossParenthetical", "http://portagebiotech.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Loss per share, basic", "verboseLabel": "Basic (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r56", "r57" ] }, "ptgef_BoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "BoardOfDirectorsMember", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Board Of Directors [Member]" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r209" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative", "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bottom of range [member]" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r108", "r117", "r122", "r161", "r163", "r209" ] }, "ifrs-full_BusinessCombinationsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BusinessCombinationsAxis", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Business combinations [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r129" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Cash", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r206" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r10", "r75", "r96" ] }, "ptgef_CashCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CashCarryingValue", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Carrying value" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } } }, "auth_ref": [ "r73", "r76" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } } }, "auth_ref": [ "r73", "r76" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Cash flows from (used in) operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } } }, "auth_ref": [ "r73", "r76" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "ptgef_CashFundDescription": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CashFundDescription", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash fund, description" } } }, "auth_ref": [] }, "ifrs-full_CashOnHand": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashOnHand", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash on hand" } }, "en": { "role": { "documentation": "The amount of cash held by the entity. This does not include demand deposits." } } }, "auth_ref": [ "r206" ] }, "ptgef_CashPaidForInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CashPaidForInterest", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest" } } }, "auth_ref": [] }, "ptgef_CashUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CashUsedInOperatingActivities", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash used in operating activities" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfFinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfFinancialAssetsAbstract", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAbstract", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative", "http://portagebiotech.com/role/LossPerShareDetails1", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative", "http://portagebiotech.com/role/Non-controllingInterestDetails", "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r43" ] }, "ptgef_ChangeInDeferredIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ChangeInDeferredIncomeTaxRate", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Change in the deferred income tax rate" } } }, "auth_ref": [] }, "ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 }, "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone", "negatedLabel": "Change in fair value of deferred purchase price payable \u2013 Tarus and deferred obligation \u2013 iOx milestone" } } }, "auth_ref": [] }, "ptgef_ChangeInFairValueOfWarrantLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ChangeInFairValueOfWarrantLiabilities", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Change in the fair value of the warrant liabilities" } } }, "auth_ref": [] }, "ptgef_ChangeInFairValueOfWarrantLiability": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ChangeInFairValueOfWarrantLiability", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Change in fair value of warrant liability ,shares" } } }, "auth_ref": [] }, "ptgef_ChangeInFairValueOfWarrantLiabilityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ChangeInFairValueOfWarrantLiabilityAmount", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Change in fair value of warrant liability, amount" } } }, "auth_ref": [] }, "ptgef_ChangeInFairValueOfWarrantLiabilityExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ChangeInFairValueOfWarrantLiabilityExercisePrice", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Change in fair value of warrant liability exercise price" } } }, "auth_ref": [] }, "ptgef_ChangeInFairValuesOfWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ChangeInFairValuesOfWarrantLiability", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Change in fair value of warrant liability" } } }, "auth_ref": [] }, "ptgef_ChangeIncreaseInDeferredIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ChangeIncreaseInDeferredIncomeTaxRate", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Change from increase in deferred income tax rate" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ptgef_ClassBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ClassBWarrantsMember", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Class B Warrants [Member]" } } }, "auth_ref": [] }, "ptgef_ClassCWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ClassCWarrantsMember", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Class C Warrants [Member]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails1", "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative", "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets and goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r200" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails", "http://portagebiotech.com/role/WarrantLiabilityDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetails2", "http://portagebiotech.com/role/WarrantLiabilityDetails3", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityTables" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r24" ] }, "ifrs-full_ClassesOfShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalMember", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails", "http://portagebiotech.com/role/WarrantLiabilityDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetails2", "http://portagebiotech.com/role/WarrantLiabilityDetails3", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityTables" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r24" ] }, "ptgef_CommitmentAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CommitmentAndContingencies", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingent Liabilities (Note 16)" } } }, "auth_ref": [] }, "ptgef_CommitmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CommitmentFee", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Commitment fee" } } }, "auth_ref": [] }, "ptgef_CommitmentFeeUnderCommittedPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CommitmentFeeUnderCommittedPurchaseAgreement", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 8.0 }, "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Commitment fee under Committed Purchase Agreement", "label": "Commitment fee under Committed Purchase Agreement" } } }, "auth_ref": [] }, "ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock", "presentation": [ "http://portagebiotech.com/role/CapitalStockTables" ], "lang": { "en-us": { "role": { "label": "Schedule of unlimited number of common shares without par value" } } }, "auth_ref": [] }, "ptgef_CommonStockCapitalShareReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CommonStockCapitalShareReservedForFutureIssuance", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock capital share reserved for future issuance" } } }, "auth_ref": [] }, "ptgef_CommonStockShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CommonStockShares", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Ordinary shares beginning balance, shares", "periodEndLabel": "Ordinary shares ending balance, shares", "label": "CommonStockShares" } } }, "auth_ref": [] }, "ptgef_CommonStockValues": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CommonStockValues", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Ordinary shares beginning balance, amount", "label": "Ordinary shares ending balance, amount", "periodEndLabel": "Ordinary shares ending balance, amount" } } }, "auth_ref": [] }, "ptgef_CompensationCommittee": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CompensationCommittee", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Compensation committee" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails", "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/StockOptionReserveDetails" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r4" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss for period", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r1", "r26", "r78", "r80", "r94", "r159" ] }, "ifrs-full_ComprehensiveIncomeAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive loss attributable to:" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss for period", "label": "Comprehensive income, attributable to owners of parent" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } } }, "auth_ref": [ "r1", "r29" ] }, "ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Owners of the Company", "label": "Comprehensive income from continuing operations, attributable to owners of parent" } }, "en": { "role": { "documentation": "The comprehensive income from continuing operations attributable to owners of the parent. [Refer: Comprehensive income from continuing operations]" } } }, "auth_ref": [ "r208" ] }, "ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-controlling interest", "label": "Comprehensive income from discontinued operations, attributable to owners of parent" } }, "en": { "role": { "documentation": "The comprehensive income from discontinued operations attributable to owners of the parent. [Refer: Comprehensive income from discontinued operations]" } } }, "auth_ref": [ "r208" ] }, "ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContingentLiabilitiesRecognisedInBusinessCombination", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "lang": { "en-us": { "role": { "label": "Total liabilities" } }, "en": { "role": { "documentation": "The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]" } } }, "auth_ref": [ "r130" ] }, "ptgef_ConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ConvertibleNote", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible note" } } }, "auth_ref": [] }, "ptgef_ConvertibleNoteDescription": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ConvertibleNoteDescription", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible note description" } } }, "auth_ref": [] }, "ptgef_ConvertibleNoteReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ConvertibleNoteReceivable", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Convertible note receivable" } } }, "auth_ref": [] }, "ptgef_ConvertibleNoteReceivableIncludingAccruedInterestNetOfImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ConvertibleNoteReceivableIncludingAccruedInterestNetOfImpairment", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Convertible note receivable, including accrued interest, net of impairment" } } }, "auth_ref": [] }, "ptgef_ConvertibleNoteShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ConvertibleNoteShares", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Note, shares" } } }, "auth_ref": [] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r135" ] }, "ifrs-full_CounterpartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CounterpartiesMember", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r135" ] }, "ptgef_CountryOfBritishVirginIslandsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CountryOfBritishVirginIslandsMember", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Country Of British Virgin Islands [Member]" } } }, "auth_ref": [] }, "ptgef_CountryOfDelawareMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CountryOfDelawareMember", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Country Of Delaware [Member]" } } }, "auth_ref": [] }, "ifrs-full_CountryOfIncorporationOrResidenceOfAssociate": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CountryOfIncorporationOrResidenceOfAssociate", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Place of Incorporation and principal place of business" } }, "en": { "role": { "documentation": "The country in which an associate of the entity is incorporated. [Refer: Associates [member]]" } } }, "auth_ref": [ "r49", "r53", "r88" ] }, "ptgef_CountryOfUnitedKingdomMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CountryOfUnitedKingdomMember", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "label": "Country Of United Kingdom [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAdvancesToSuppliers", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "parentTag": "ifrs-full_CurrentPrepayments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid insurance" } }, "en": { "role": { "documentation": "The amount of current advances made to suppliers before goods or services are received." } } }, "auth_ref": [ "r192" ] }, "ptgef_CurrentAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CurrentAsset", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Current assets", "label": "Current Asset" } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets [Default Label]" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r17", "r90", "r159" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "auth_ref": [] }, "ptgef_CurrentFederalIncomeTaxBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CurrentFederalIncomeTaxBenefit", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Federal" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ptgef_CurrentForeignIncomeTaxBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CurrentForeignIncomeTaxBenefit", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign" } } }, "auth_ref": [] }, "ifrs-full_CurrentInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentInvestments", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Investment in associate", "label": "Current investments" } }, "en": { "role": { "documentation": "The amount of current investments." } } }, "auth_ref": [ "r193" ] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition", "http://portagebiotech.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "Lease liability - current, including interest", "verboseLabel": "Lease liability - current", "terseLabel": "Lease liability current" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r112" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities [Default Label]" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r18", "r92", "r159" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "auth_ref": [] }, "ptgef_CurrentLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CurrentLosses", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Current losses" } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "parentTag": "ifrs-full_CurrentPrepayments", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r192" ] }, "ifrs-full_CurrentPrepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentPrepayments", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total prepaid expenses and other receivables", "label": "Current prepayments" } }, "en": { "role": { "documentation": "The amount of current prepayments. [Refer: Prepayments]" } } }, "auth_ref": [ "r150" ] }, "ifrs-full_CurrentReceivablesFromSaleOfProperties": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentReceivablesFromSaleOfProperties", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "parentTag": "ifrs-full_CurrentPrepayments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid clinical research costs" } }, "en": { "role": { "documentation": "The amount of current receivables from sale of properties. [Refer: Receivables from sale of properties]" } } }, "auth_ref": [ "r194" ] }, "ptgef_CurrentStateAndLocalIncomeTaxBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "CurrentStateAndLocalIncomeTaxBenefit", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "State and local" } } }, "auth_ref": [] }, "ifrs-full_CurrentTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxExpenseIncome", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Total current" } }, "en": { "role": { "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } } }, "auth_ref": [ "r154" ] }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Current:" } } }, "auth_ref": [] }, "ptgef_DeRecognitionOfDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeRecognitionOfDeferredTaxAssets", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Derecognition of deferred tax assets" } } }, "auth_ref": [] }, "ptgef_DecreasingCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DecreasingCarryingValue", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Decreasing the carrying value" } } }, "auth_ref": [] }, "ptgef_DecreasingImpairmentCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DecreasingImpairmentCarryingValue", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Decreasing impairment carrying value" } } }, "auth_ref": [] }, "ptgef_DeferredCommitmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredCommitmentFee", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Deferred commitment fee, net of amortization of $450 and $61, respectively" } } }, "auth_ref": [] }, "ptgef_DeferredCommitmentFeeNetOfAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredCommitmentFeeNetOfAmortization", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPositionParenthetical" ], "lang": { "en-us": { "role": { "label": "Deferred commitment fee, net of amortization" } } }, "auth_ref": [] }, "ptgef_DeferredFederalIncomeTaxBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredFederalIncomeTaxBenefit", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Federal", "label": "DeferredFederalIncomeTaxBenefit" } } }, "auth_ref": [] }, "ptgef_DeferredForeignIncomeTaxBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredForeignIncomeTaxBenefit", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign", "label": "DeferredForeignIncomeTaxBenefit" } } }, "auth_ref": [] }, "ptgef_DeferredObligationIoxMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredObligationIoxMilestone", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Deferred obligation - iOx milestone" } } }, "auth_ref": [] }, "ptgef_DeferredObligationIoxMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredObligationIoxMilestones", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred obligation - iOx milestone", "label": "DeferredObligationIoxMilestones" } } }, "auth_ref": [] }, "ptgef_DeferredPurchasePricePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredPurchasePricePayable", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred purchase price payable" } } }, "auth_ref": [] }, "ptgef_DeferredPurchasePricePayableTarus": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredPurchasePricePayableTarus", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Deferred purchase price payable - Tarus" } } }, "auth_ref": [] }, "ptgef_DeferredStateAndLocalIncomeTaxBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredStateAndLocalIncomeTaxBenefit", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "State and local", "label": "DeferredStateAndLocalIncomeTaxBenefit" } } }, "auth_ref": [] }, "ptgef_DeferredTaxAssetUnrecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredTaxAssetUnrecognized", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/IncomeTaxesDetails4": { "parentTag": "ifrs-full_NetDeferredTaxAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Deferred tax asset (unrecognized)" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r12", "r16", "r37" ] }, "ptgef_DeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredTaxAssetsAbstract", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "auth_ref": [] }, "ptgef_DeferredTaxAssetsNetOperatingLossCarryforward": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredTaxAssetsNetOperatingLossCarryforward", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/IncomeTaxesDetails4": { "parentTag": "ifrs-full_NetDeferredTaxAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Net operating loss" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxExpenseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxExpenseIncomeAbstract", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred:" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Deferred tax liability" } }, "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r12", "r16", "r37" ] }, "ptgef_DeferredTaxLiabilitiesInProcessRAndD": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredTaxLiabilitiesInProcessRAndD", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/IncomeTaxesDetails4": { "parentTag": "ptgef_DeferredTaxLiability1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "verboseLabel": "In-process research and development", "label": "DeferredTaxLiabilitiesInProcessRAndD" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "lang": { "en-us": { "role": { "label": "Deferred purchase consideration at fair value" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]" } } }, "auth_ref": [ "r207" ] }, "ptgef_DeferredTaxLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredTaxLiability", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities" } } }, "auth_ref": [] }, "ptgef_DeferredTaxLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredTaxLiability1", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/IncomeTaxesDetails4": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax liability", "label": "DeferredTaxLiability1" } } }, "auth_ref": [] }, "ptgef_DeferredTaxLiabiltiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredTaxLiabiltiesAbstract", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "auth_ref": [] }, "ptgef_DeferredTaxesLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DeferredTaxesLiability", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred tax liability", "label": "DeferredTaxesLiability" } } }, "auth_ref": [] }, "ifrs-full_DefinedBenefitPlansAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DefinedBenefitPlansAxis", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined benefit plans [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r39" ] }, "ifrs-full_DefinedBenefitPlansMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DefinedBenefitPlansMember", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used." } } }, "auth_ref": [ "r39" ] }, "ptgef_DenominatorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DenominatorAbstract", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Denominator (in 000\u2019)" } } }, "auth_ref": [] }, "ifrs-full_DepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Depreciation expense", "label": "Depreciation and amortisation expense" } }, "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } } }, "auth_ref": [ "r0", "r31", "r97", "r138", "r145", "r147" ] }, "ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory", "presentation": [ "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetails2", "http://portagebiotech.com/role/WarrantLiabilityDetails3" ], "lang": { "en-us": { "role": { "label": "Expected volatility" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r123" ] }, "ifrs-full_DescriptionOfNatureOfNonadjustingEventAfterReportingPeriod": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfNatureOfNonadjustingEventAfterReportingPeriod", "presentation": [ "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of nature of non-adjusting event after reporting period" } }, "en": { "role": { "documentation": "The description of the nature of a non-adjusting event after the reporting period. [Refer: Non-adjusting events after reporting period [member]]" } } }, "auth_ref": [ "r32" ] }, "ptgef_DescriptionOfNatureOfPurchaseAgreement": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DescriptionOfNatureOfPurchaseAgreement", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description reporting period" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetails2", "http://portagebiotech.com/role/WarrantLiabilityDetails3" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate", "verboseLabel": "Risk-free interest rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r123" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLossParenthetical", "http://portagebiotech.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Loss per share, diluted", "verboseLabel": "Diluted (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r56", "r57" ] }, "ptgef_DisclosureAcquisitionOfTarusAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureAcquisitionOfTarusAbstract", "lang": { "en-us": { "role": { "label": "Acquisition Of Tarus" } } }, "auth_ref": [] }, "ptgef_DisclosureCapitalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureCapitalDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Capital Disclosures" } } }, "auth_ref": [] }, "ptgef_DisclosureCapitalStockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureCapitalStockAbstract", "lang": { "en-us": { "role": { "label": "Capital Stock" } } }, "auth_ref": [] }, "ptgef_DisclosureEventsAfterBalanceSheetDateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureEventsAfterBalanceSheetDateAbstract", "lang": { "en-us": { "role": { "label": "Events After Balance Sheet Date" } } }, "auth_ref": [] }, "ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureFinancialInstrumentsAndRiskManagementAbstract", "lang": { "en-us": { "role": { "label": "Financial Instruments And Risk Management" } } }, "auth_ref": [] }, "ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract", "lang": { "en-us": { "role": { "label": "In-process Research And Development And Deferred Tax Liability" } } }, "auth_ref": [] }, "ptgef_DisclosureInvestmentInAssociateAndConvertibleNoteReceivableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureInvestmentInAssociateAndConvertibleNoteReceivableAbstract", "lang": { "en-us": { "role": { "label": "Investment In Associate And Convertible Note Receivable" } } }, "auth_ref": [] }, "ptgef_DisclosureInvestmentInPublicCompanyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureInvestmentInPublicCompanyAbstract", "lang": { "en-us": { "role": { "label": "Investment In Public Company" } } }, "auth_ref": [] }, "ptgef_DisclosureNatureOfOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureNatureOfOperationsAbstract", "lang": { "en-us": { "role": { "label": "Nature Of Operations" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfBasisOfConsolidationExplanatory", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION" } }, "en": { "role": { "documentation": "The disclosure of the basis used for consolidation." } } }, "auth_ref": [ "r190" ] }, "ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureOfCapitalManagementExplanatoryTextBlock", "presentation": [ "http://portagebiotech.com/role/CapitalDisclosures" ], "lang": { "en-us": { "role": { "label": "CAPITAL DISCLOSURES" } } }, "auth_ref": [] }, "ptgef_DisclosureOfCapitalStockExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureOfCapitalStockExplanatory", "presentation": [ "http://portagebiotech.com/role/CapitalStock" ], "lang": { "en-us": { "role": { "label": "CAPITAL STOCK" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENT LIABILITIES" } }, "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r190" ] }, "ptgef_DisclosureOfDeferredTaxAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureOfDeferredTaxAssetsTableTextBlock", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of deferred tax assets and liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansTable", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2" ], "lang": { "en-us": { "role": { "label": "Disclosure of defined benefit plans [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } } }, "auth_ref": [ "r39" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r209" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutInvestmentPropertyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutInvestmentPropertyExplanatory", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableTables" ], "lang": { "en-us": { "role": { "label": "Schedule of investment in stimunity" } }, "en": { "role": { "documentation": "The disclosure of detailed information about investment property. [Refer: Investment property]" } } }, "auth_ref": [ "r67" ] }, "ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock", "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of prepaid expense and other receivables" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r109" ] }, "ptgef_DisclosureOfEventAfterBalanceSheetDateExpanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureOfEventAfterBalanceSheetDateExpanatory", "presentation": [ "http://portagebiotech.com/role/EventsAfterBalanceSheetDate" ], "lang": { "en-us": { "role": { "label": "EVENTS AFTER THE BALANCE SHEET DATE" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueMeasurementExplanatory", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of fair value" } }, "en": { "role": { "documentation": "The entire disclosure for fair value measurement." } } }, "auth_ref": [ "r107" ] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsTable", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the fair value measurement of assets." } } }, "auth_ref": [ "r106" ] }, "ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" ], "lang": { "en-us": { "role": { "label": "Schedule of financial instrument" } } }, "auth_ref": [] }, "ptgef_DisclosureOfFinancialInstrumentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureOfFinancialInstrumentExplanatory", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" ], "lang": { "en-us": { "role": { "label": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGoingConcernExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGoingConcernExplanatory", "presentation": [ "http://portagebiotech.com/role/GoingConcern" ], "lang": { "en-us": { "role": { "label": "GOING CONCERN" } }, "en": { "role": { "documentation": "The disclosure of the entity's ability to continue as a going concern." } } }, "auth_ref": [ "r190" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://portagebiotech.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r38" ] }, "ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInterestsInOtherEntitiesExplanatory", "presentation": [ "http://portagebiotech.com/role/Non-controllingInterest" ], "lang": { "en-us": { "role": { "label": "NON-CONTROLLING INTEREST" } }, "en": { "role": { "documentation": "The entire disclosure for interests in other entities." } } }, "auth_ref": [ "r82" ] }, "ptgef_DisclosureOfInvestmentAssociatetableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureOfInvestmentAssociatetableTextBlock", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableTables" ], "lang": { "en-us": { "role": { "label": "Schedule of investment associate" } } }, "auth_ref": [] }, "ptgef_DisclosureOfInvestmentInPublicCompaniesExplanatoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureOfInvestmentInPublicCompaniesExplanatoryTextBlock", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompany" ], "lang": { "en-us": { "role": { "label": "INVESTMENT IN PUBLIC COMPANY" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInvestmentPropertyTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInvestmentPropertyTable", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about investment property [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of investment property." } } }, "auth_ref": [ "r67" ] }, "ptgef_DisclosureOfIputsAssociatedFairValueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureOfIputsAssociatedFairValueExplanatory", "presentation": [ "http://portagebiotech.com/role/CapitalStockTables" ], "lang": { "en-us": { "role": { "label": "Schedule of associated fair value" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfLeasesExplanatory", "presentation": [ "http://portagebiotech.com/role/Lease" ], "lang": { "en-us": { "role": { "label": "LEASE" } }, "en": { "role": { "documentation": "The entire disclosure for leases." } } }, "auth_ref": [ "r115", "r116" ] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "presentation": [ "http://portagebiotech.com/role/LeaseTables" ], "lang": { "en-us": { "role": { "label": "Schedule of lease liability" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r114" ] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "presentation": [ "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } } }, "auth_ref": [ "r33" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveTables" ], "lang": { "en-us": { "role": { "label": "Schedule of weighted average exercise price" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r122" ] }, "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOffsettingOfFinancialAssetsTable", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of offsetting of financial assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the offsetting of financial assets." } } }, "auth_ref": [ "r134" ] }, "ifrs-full_DisclosureOfOtherAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherAssetsExplanatory", "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" ], "lang": { "en-us": { "role": { "label": "PREPAID EXPENSES AND OTHER RECEIVABLES" } }, "en": { "role": { "documentation": "The disclosure of other assets. [Refer: Other assets]" } } }, "auth_ref": [ "r190" ] }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails1", "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of changes in intangible assets and goodwill." } } }, "auth_ref": [ "r200" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r44" ] }, "ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveTables" ], "lang": { "en-us": { "role": { "label": "Schedule of changes in the number of options issued" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://portagebiotech.com/role/StockOptionReserve" ], "lang": { "en-us": { "role": { "label": "STOCK OPTION RESERVE" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r118" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails", "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to associates." } } }, "auth_ref": [ "r51", "r55", "r102" ] }, "ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "presentation": [ "http://portagebiotech.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "ptgef_DisclosureOfTermsStockOptionReserveExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureOfTermsStockOptionReserveExplanatory", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveTables" ], "lang": { "en-us": { "role": { "label": "Schedule of stock option reserve" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative", "http://portagebiotech.com/role/LossPerShareDetails1", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative", "http://portagebiotech.com/role/Non-controllingInterestDetails", "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r43" ] }, "ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations." } } }, "auth_ref": [ "r128" ] }, "ptgef_DisclosureSignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureSignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] }, "ptgef_DisclosureWarrantLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "DisclosureWarrantLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Warrant Liability" } } }, "auth_ref": [] }, "ifrs-full_DistributionCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DistributionCosts", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 4.0 }, "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Offering costs", "label": "Offering costs" } }, "en": { "role": { "documentation": "The amount of costs relating to the distribution of goods and services." } } }, "auth_ref": [ "r31", "r148" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r183" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r181", "r183", "r184" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r182" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r170" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r183" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r183" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r185" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r173" ] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Loss per share" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://portagebiotech.com/role/LossPerShare" ], "lang": { "en-us": { "role": { "label": "(LOSS) PER SHARE" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r56" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r176" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r172" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r172" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r189" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r172" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r186" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r184" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r172" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r172" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r172" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r172" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r187" ] }, "ifrs-full_EntitysTotalForAssociatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForAssociatesMember", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails", "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "auth_ref": [ "r51", "r55", "r102" ] }, "ifrs-full_EntitysTotalForBusinessCombinationsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForBusinessCombinationsMember", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used." } } }, "auth_ref": [ "r129", "r132" ] }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForRelatedPartiesMember", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative", "http://portagebiotech.com/role/LossPerShareDetails1", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative", "http://portagebiotech.com/role/Non-controllingInterestDetails", "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r43" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r15", "r20", "r77", "r79", "r103", "r104", "r105" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r15" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity" } } }, "auth_ref": [] }, "ifrs-full_EquityAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Total equity attributable to owners of the Company" } }, "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } } }, "auth_ref": [ "r14" ] }, "ifrs-full_EquityAttributableToOwnersOfParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAttributableToOwnersOfParentMember", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity attributable to owners of parent [member]" } }, "en": { "role": { "documentation": "This member stands for equity attributable to the owners of the parent." } } }, "auth_ref": [ "r4" ] }, "ptgef_EquityInLossIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "EquityInLossIncome", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity in (loss) income" } } }, "auth_ref": [] }, "ptgef_EquityIncentivePlanIncreasedShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "EquityIncentivePlanIncreasedShares", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity incentive plan increased shares" } } }, "auth_ref": [] }, "ifrs-full_EquityInterestsOfAcquirer": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityInterestsOfAcquirer", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity interests of acquirer" } }, "en": { "role": { "documentation": "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r126" ] }, "ifrs-full_EquityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityMember", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails", "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/StockOptionReserveDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r4" ] }, "ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ExcessOfNoncontrollingInterestAcquiredOverConsiderationIox", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Excess of non-controlling interest acquired over consideration - iOx" } } }, "auth_ref": [] }, "ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ExcessOfNoncontrollingInterestAcquiredOverConsiderationIoxShares", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "label": "Excess of non-controlling interest acquired over consideration iOx, shares" } } }, "auth_ref": [] }, "ptgef_ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ExcessOfNoncontrollingInterestAcquiredOverConsiderationsIox", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "label": "Excess of non-controlling interest acquired over consideration iOx, amount" } } }, "auth_ref": [] }, "ptgef_ExchangeOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ExchangeOfOrdinaryShares", "presentation": [ "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exchange of ordinary shares" } } }, "auth_ref": [] }, "ptgef_ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ExchangeOfStimunityConvertibleNoteForStimunitySharesAtFairValue", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Exchange of Stimunity Convertible Note for Stimunity shares at fair value" } } }, "auth_ref": [] }, "ptgef_ExecutiveMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ExecutiveMember", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Executive [Member]" } } }, "auth_ref": [] }, "ptgef_ExercisableAggregateOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ExercisableAggregateOrdinaryShares", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercisable aggregate ordinary shares" } } }, "auth_ref": [] }, "ptgef_ExercisablePrice": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ExercisablePrice", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercisable price" } } }, "auth_ref": [] }, "ptgef_ExercisePerPrice": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ExercisePerPrice", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise per price" } } }, "auth_ref": [] }, "ptgef_ExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ExercisePrice", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise price", "label": "ExercisePrice" } } }, "auth_ref": [] }, "ptgef_ExercisePriceFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ExercisePriceFairValue", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetails2", "http://portagebiotech.com/role/WarrantLiabilityDetails3" ], "lang": { "en-us": { "role": { "label": "Exercise price" } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExercisePriceOfOutstandingShareOptions2019", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise price", "label": "Exercise price of outstanding share options" } }, "en": { "role": { "documentation": "The exercise price of outstanding share options." } } }, "auth_ref": [ "r122" ] }, "ptgef_ExercisePriceOfOutstandingWarrant": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ExercisePriceOfOutstandingWarrant", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise price", "label": "ExercisePriceOfOutstandingWarrant" } } }, "auth_ref": [] }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExercisePriceShareOptionsGranted2019", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails1", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise price", "terseLabel": "Exercisable price", "label": "Exercise price, share options granted" } }, "en": { "role": { "documentation": "The exercise price of share options granted." } } }, "auth_ref": [ "r123" ] }, "ptgef_ExercisePriceWarrantPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ExercisePriceWarrantPerShare", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price warrant per share" } } }, "auth_ref": [] }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetails2", "http://portagebiotech.com/role/WarrantLiabilityDetails3" ], "lang": { "en-us": { "role": { "label": "Expected dividend", "verboseLabel": "Dividend yield" } }, "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } } }, "auth_ref": [ "r123" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "ptgef_FairValueOfDeferredObligationIoxMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "FairValueOfDeferredObligationIoxMilestone", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Fair value of deferred obligation \u2013 iOx milestone" } } }, "auth_ref": [] }, "ptgef_FairValueOfDeferredPurchasePricePayableTarus": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "FairValueOfDeferredPurchasePricePayableTarus", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Fair value of deferred purchase price payable \u2013 Tarus" } } }, "auth_ref": [] }, "ptgef_FairValueOfSharesIssuedForCommitmentFeesCommittedPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "FairValueOfSharesIssuedForCommitmentFeesCommittedPurchaseAgreement", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Fair value of shares issued for commitment fees \u2013 Committed Purchase Agreement" } } }, "auth_ref": [] }, "ptgef_FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "FairValueOfSharesIssuedForNoncontrollingInterestPurchaseOfIox", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Fair value of shares issued for non-controlling interest purchase of iOx" } } }, "auth_ref": [] }, "ptgef_FairValueOfSharesIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "FairValueOfSharesIssuedForServices", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Fair value of shares issued for services" } } }, "auth_ref": [] }, "ptgef_FairValueOfSharesIssuedForTarus": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "FairValueOfSharesIssuedForTarus", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Fair value of shares issued for Tarus" } } }, "auth_ref": [] }, "ptgef_FairValueOfWarrantPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "FairValueOfWarrantPerShare", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of warrant per share" } } }, "auth_ref": [] }, "ptgef_FairValueOfWarrantsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "FairValueOfWarrantsAmount", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants amount" } } }, "auth_ref": [] }, "ptgef_FairValueOfWarrantsAtIssuanceExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "FairValueOfWarrantsAtIssuanceExercisePrice", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants at issuance exercise price" } } }, "auth_ref": [] }, "ptgef_FairValueOfWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "FairValueOfWarrantsShares", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Fair value of warrants shares" } } }, "auth_ref": [] }, "ptgef_FairValueThroughProfitOrLossMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "FairValueThroughProfitOrLossMember", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Through Profit Or Loss [Member]" } } }, "auth_ref": [] }, "ptgef_FairValueToOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "FairValueToOtherComprehensiveIncomeMember", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value To Other Comprehensive Income [Member]" } } }, "auth_ref": [] }, "ptgef_FederalNetOperatingLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "FederalNetOperatingLosses", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Federal net operating losses" } } }, "auth_ref": [] }, "ifrs-full_FeeAndCommissionExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FeeAndCommissionExpense", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Clearing fees" } }, "en": { "role": { "documentation": "The amount of expense relating to fees and commissions." } } }, "auth_ref": [ "r195" ] }, "ptgef_ForeignCurrencyEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ForeignCurrencyEffect", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Foreign currency effect" } } }, "auth_ref": [] }, "ptgef_ForeignExchangeTransactionGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ForeignExchangeTransactionGainLoss", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Foreign exchange transaction gain (loss)" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign exchange transaction loss", "label": "Foreign exchange gain (loss)" } }, "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } } }, "auth_ref": [ "r5", "r41" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative expenses" } }, "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } } }, "auth_ref": [ "r192" ] }, "ifrs-full_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill" } }, "en": { "role": { "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r7", "r63", "r64", "r131" ] }, "ptgef_GrossProceedsFromStock": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "GrossProceedsFromStock", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds from stock" } } }, "auth_ref": [] }, "ptgef_GrossProceedsFromStockSold": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "GrossProceedsFromStockSold", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds from stock sold" } } }, "auth_ref": [] }, "ptgef_GrossProceedsRaisedInOfferings": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "GrossProceedsRaisedInOfferings", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds raised in offerings" } } }, "auth_ref": [] }, "ptgef_GrossProceedsReceivedInOfferings": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "GrossProceedsReceivedInOfferings", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds received in Offerings" } } }, "auth_ref": [] }, "ptgef_HCWainwrightMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "HCWainwrightMember", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "H C Wainwright [Member]" } } }, "auth_ref": [] }, "ptgef_IMM60IOXMelanomaLungCancersMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IMM60IOXMelanomaLungCancersMember", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "I M M 60 I O X Melanoma Lung Cancers [Member]" } } }, "auth_ref": [] }, "ptgef_IMM65IOXMelanomaLungCancersMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IMM65IOXMelanomaLungCancersMember", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "I M M 65 I O X Melanoma Lung Cancers [Member]" } } }, "auth_ref": [] }, "ptgef_IOXMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IOXMember", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative", "http://portagebiotech.com/role/Non-controllingInterestDetails" ], "lang": { "en-us": { "role": { "label": "I O X [Member]" } } }, "auth_ref": [] }, "ptgef_IOXOptionPlanAndSubsidiaryPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IOXOptionPlanAndSubsidiaryPlanMember", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2" ], "lang": { "en-us": { "role": { "label": "I O X Option Plan And Subsidiary Plan [Member]" } } }, "auth_ref": [] }, "ptgef_IPRDMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IPRDMember", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "I P R D [Member]" } } }, "auth_ref": [] }, "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities assumed" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r166", "r167" ] }, "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "lang": { "en-us": { "role": { "label": "Identifiable intangible assets" } }, "en": { "role": { "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]" } } }, "auth_ref": [ "r166", "r167" ] }, "ptgef_IfrsStatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IfrsStatementLineItems", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative", "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/CapitalStockDetails", "http://portagebiotech.com/role/CapitalStockDetails1", "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "http://portagebiotech.com/role/IncomeTaxesDetails3", "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative", "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails", "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetailsNarrative", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative", "http://portagebiotech.com/role/LossPerShareDetails1", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative", "http://portagebiotech.com/role/Non-controllingInterestDetails", "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative", "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://portagebiotech.com/role/StockOptionReserveDetails", "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityDetails", "http://portagebiotech.com/role/WarrantLiabilityDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetails2", "http://portagebiotech.com/role/WarrantLiabilityDetails3", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityTables" ], "lang": { "en-us": { "role": { "label": "IfrsStatementLineItems [Line Items]" } } }, "auth_ref": [] }, "ptgef_ImmediatelyExercisableAndExpire": { "xbrltype": "durationItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ImmediatelyExercisableAndExpire", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Immediately exercisable and expire" } } }, "auth_ref": [] }, "ptgef_ImpairmentAnalysis": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ImpairmentAnalysis", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Impairment analysis" } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLoss", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails1", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Share of loss", "terseLabel": "Impairment loss", "label": "Impairment loss [Default Label]" } }, "en": { "role": { "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r61", "r62" ] }, "ptgef_ImpairmentLossIoxIprd": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ImpairmentLossIoxIprd", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 4.0 }, "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Impairment loss - iOx IPR&D", "label": "Impairment loss - iOx IPR&D" } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLoss", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss on impairment" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss. [Refer: Impairment loss; Profit (loss)]" } } }, "auth_ref": [ "r59", "r60" ] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossInvestmentProperty": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossInvestmentProperty", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrealized gain or loss" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for investment property. [Refer: Impairment loss recognised in profit or loss; Investment property]" } } }, "auth_ref": [ "r68", "r70" ] }, "ptgef_ImpairmentLossStimunity": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ImpairmentLossStimunity", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Impairment loss - Stimunity", "label": "Impairment loss - Stimunity" } } }, "auth_ref": [] }, "ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiabilityExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "InProcessResearchAndDevelopmentAndDeferredTaxLiabilityExplanatory", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" ], "lang": { "en-us": { "role": { "label": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY" } } }, "auth_ref": [] }, "ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IncomeLossOnOrdinaryActivitiesBeforeTax", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Loss on ordinary activities before tax" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ptgef_IncomeTaxBenefitExpenseAtStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IncomeTaxBenefitExpenseAtStatutoryIncomeTaxRate", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Income tax benefit at statutory income tax rate" } } }, "auth_ref": [] }, "ptgef_IncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IncomeTaxExpense", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Income tax (expense)" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ptgef_NetLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax benefit (expense)", "label": "Tax expense (income)" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r30", "r34", "r35", "r36", "r46", "r100", "r139" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Decrease in cash and cash equivalents during period", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r75" ] }, "ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInDeferredTaxLiabilityAsset", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in deferred tax liability", "label": "Increase (decrease) in deferred tax liability (asset)" } }, "en": { "role": { "documentation": "The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]" } } }, "auth_ref": [ "r197" ] }, "ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInFairValueMeasurementLiabilities", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Excess of the fair value of the warrant liabilities" } }, "en": { "role": { "documentation": "The increase (decrease) in the fair value measurement of liabilities. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r105" ] }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issued or accrued for services, shares", "label": "Increase (decrease) in number of ordinary shares issued" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r192" ] }, "ptgef_IncreaseDecreaseInShareOfLossInAssociate": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IncreaseDecreaseInShareOfLossInAssociate", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share of loss in associate" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-based compensation expense" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r3" ] }, "ptgef_IncreasingDecreasingAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IncreasingDecreasingAccountsReceivable", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts receivable" } } }, "auth_ref": [] }, "ptgef_InprocessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "InprocessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "In-process research and development" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsAndGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsAndGoodwillMember", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails1", "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative", "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r200" ] }, "ptgef_IntensityMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IntensityMember", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intensity [Member]" } } }, "auth_ref": [] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest expense" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r99", "r137", "r145" ] }, "ifrs-full_InvestmentAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InvestmentAccountedForUsingEquityMethod", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Investments accounted for using equity method" } }, "en": { "role": { "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]" } } }, "auth_ref": [ "r8", "r101", "r141" ] }, "ptgef_InvestmentInAssociateAndConvertibleNoteReceivableDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "InvestmentInAssociateAndConvertibleNoteReceivableDisclosureTextBlock", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivable" ], "lang": { "en-us": { "role": { "label": "INVESTMENT IN ASSOCIATE AND CONVERTIBLE NOTE RECEIVABLE" } } }, "auth_ref": [] }, "ptgef_InvestmentInPrivateCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "InvestmentInPrivateCompany", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Investment in public company", "label": "InvestmentInPrivateCompany" } } }, "auth_ref": [] }, "ptgef_InvestmentOwnedShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "InvestmentOwnedShares", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Acquisition of shares" } } }, "auth_ref": [] }, "ptgef_InvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "InvestmentOwnershipPercentage", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of equity held" } } }, "auth_ref": [] }, "ifrs-full_InvestmentProperty": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InvestmentProperty", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Investment in public company" } }, "en": { "role": { "documentation": "The amount of property (land or a building - or part of a building - or both) held (by the owner or by the lessee as a right-of-use asset) to earn rentals or for capital appreciation or both, rather than for: (a) use in the production or supply of goods or services or for administrative purposes; or (b) sale in the ordinary course of business." } } }, "auth_ref": [ "r6", "r69", "r71" ] }, "ifrs-full_InvestmentPropertyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InvestmentPropertyMember", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for investment property. It also represents the standard value for the 'Types of investment property' axis if no other member is used. [Refer: Investment property]" } } }, "auth_ref": [ "r160", "r162", "r192" ] }, "ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InvestmentsInSubsidiariesJointVenturesAndAssociates", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Investment in associate" } }, "en": { "role": { "documentation": "The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]" } } }, "auth_ref": [ "r47" ] }, "ptgef_IssuanceAndSalesShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IssuanceAndSalesShares", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance and sales, shares" } } }, "auth_ref": [] }, "ptgef_IssuanceOfUnsecuredNotesDescription": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "IssuanceOfUnsecuredNotesDescription", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of unsecured notes, description" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Capital stock" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r151" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails", "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r4" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share based compensation expense" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r42" ] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "Total lease liability" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r112" ] }, "ptgef_LeaseLiabilityIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LeaseLiabilityIncurred", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Lease liability incurred" } } }, "auth_ref": [] }, "ptgef_LeaseLiabilityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LeaseLiabilityInterest", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "Less: interest" } } }, "auth_ref": [] }, "ptgef_LesseeOperatingLeaseLiabilityPaymentDue": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LesseeOperatingLeaseLiabilityPaymentDue", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "Total" } } }, "auth_ref": [] }, "ptgef_LesseeOperatingLeaseLiabilityPaymentDueInRollingYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LesseeOperatingLeaseLiabilityPaymentDueInRollingYearFive", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "2028" } } }, "auth_ref": [] }, "ptgef_LesseeOperatingLeaseLiabilityPaymentDueInRollingYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LesseeOperatingLeaseLiabilityPaymentDueInRollingYearFour", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "2027" } } }, "auth_ref": [] }, "ptgef_LesseeOperatingLeaseLiabilityPaymentDueInRollingYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LesseeOperatingLeaseLiabilityPaymentDueInRollingYearThree", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "2026" } } }, "auth_ref": [] }, "ptgef_LesseeOperatingLeaseLiabilityPaymentDueInRollingYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LesseeOperatingLeaseLiabilityPaymentDueInRollingYearTwo", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "2025" } } }, "auth_ref": [] }, "ptgef_LesseeOperatingLeaseLiabilityPaymentDueNextRollingTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LesseeOperatingLeaseLiabilityPaymentDueNextRollingTwelveMonths", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "2024" } } }, "auth_ref": [] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r40", "r104" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r15", "r103", "r104", "r105", "r140", "r144" ] }, "ptgef_LiabilitiesAssumedInTarusAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LiabilitiesAssumedInTarusAcquisition", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Liabilities assumed in Tarus acquisition" } } }, "auth_ref": [] }, "ptgef_LincolnMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LincolnMember", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lincoln [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ifrs-full_LongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LongtermDeposits", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/LeaseDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Security deposit" } }, "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } } }, "auth_ref": [ "r193" ] }, "ptgef_LossBeforeProvisionForIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LossBeforeProvisionForIncomeTax", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails1" ], "lang": { "en-us": { "role": { "label": "Loss before provision for income taxes" } } }, "auth_ref": [] }, "ptgef_LossForWhichNoBenefitWasTaken": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LossForWhichNoBenefitWasTaken", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "label": "Loss for which no benefit was taken" } } }, "auth_ref": [] }, "ptgef_LossFromChangeIncreaseInFairValueOfLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LossFromChangeIncreaseInFairValueOfLiability", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss from change increase in the fair value of the liability" } } }, "auth_ref": [] }, "ptgef_LossIncomeOnFairValueOfWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LossIncomeOnFairValueOfWarrantLiability", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value of warrant liability", "label": "LossIncomeOnFairValueOfWarrantLiability" } } }, "auth_ref": [] }, "ptgef_LossOnDecreaseInFairValueOfLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LossOnDecreaseInFairValueOfLiability", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss on decrease in fair value of the liability" } } }, "auth_ref": [] }, "ptgef_LossOnImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LossOnImpairment", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails1" ], "lang": { "en-us": { "role": { "label": "Impairment loss" } } }, "auth_ref": [] }, "ptgef_LossOnRegisteredDirectOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LossOnRegisteredDirectOffering", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 3.0 }, "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on Registered Direct Offering", "label": "Loss on Registered Direct Offering" } } }, "auth_ref": [] }, "ptgef_LossOnWarrantLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LossOnWarrantLiabilities", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss on warrant liabilities" } } }, "auth_ref": [] }, "ptgef_LossPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LossPerShare", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "Loss per share", "label": "LossPerShare" } } }, "auth_ref": [] }, "ptgef_LossesNotSubjectToTax": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "LossesNotSubjectToTax", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "label": "Losses not subject to tax" } } }, "auth_ref": [] }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MajorOrdinaryShareTransactionsMember", "presentation": [ "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Major ordinary share transactions [member]" } }, "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r153" ] }, "ptgef_ManagementFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ManagementFeePercentage", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Management fee percentage" } } }, "auth_ref": [] }, "ptgef_MaximumAggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "MaximumAggregateOfferingPrice", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum aggregate offering price" } } }, "auth_ref": [] }, "ifrs-full_MeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MeasurementAxis", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r67", "r72", "r103" ] }, "ptgef_MilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "MilestonePayment", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Milestone payment" } } }, "auth_ref": [] }, "ptgef_MinorityInterestPercentage": { "xbrltype": "percentItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "MinorityInterestPercentage", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minority interest, percentage" } } }, "auth_ref": [] }, "ifrs-full_NameOfAssociate": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NameOfAssociate", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Name" } }, "en": { "role": { "documentation": "The name of an associate. [Refer: Associates [member]]" } } }, "auth_ref": [ "r48", "r52", "r87" ] }, "ptgef_NatureOfOperationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NatureOfOperationsExplanatory", "presentation": [ "http://portagebiotech.com/role/NatureOfOperations" ], "lang": { "en-us": { "role": { "label": "NATURE OF OPERATIONS" } } }, "auth_ref": [] }, "ptgef_NetChangeInWorkingCapitalComponentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NetChangeInWorkingCapitalComponentsAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating working capital:" } } }, "auth_ref": [] }, "ifrs-full_NetDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetDeferredTaxAssets", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/IncomeTaxesDetails4": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax asset", "label": "Net deferred tax assets" } }, "en": { "role": { "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r196" ] }, "ifrs-full_NetDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetDeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "lang": { "en-us": { "role": { "label": "Net deferred tax liability" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r196" ] }, "ptgef_NetLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NetLoss", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "NetLoss" } } }, "auth_ref": [] }, "ptgef_NetLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NetLossAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/Non-controllingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Net (loss) attributable to non-controlling interest" } } }, "auth_ref": [] }, "ptgef_NetLossIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NetLossIncome", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net loss" } } }, "auth_ref": [] }, "ptgef_NetProceedsFromStockSold": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NetProceedsFromStockSold", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net proceeds from stock sold" } } }, "auth_ref": [] }, "ptgef_NetProceedsToOfferings": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NetProceedsToOfferings", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net proceeds to offerings" } } }, "auth_ref": [] }, "ptgef_NetProceedsWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NetProceedsWarrantLiability", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net proceeds warrant liability" } } }, "auth_ref": [] }, "ptgef_NetUnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NetUnrealizedGainLossOnInvestments", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Net unrealized gain (loss) on investments" } } }, "auth_ref": [] }, "ptgef_NetUnrealizedGainOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NetUnrealizedGainOnInvestments", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Net unrealized loss on investments" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ptgef_NonExecutiveBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NonExecutiveBoardMember", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non Executive Board [Member]" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r33" ] }, "ifrs-full_NonadjustingEventsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsMember", "presentation": [ "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r33" ] }, "ptgef_NoncashInvestingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NoncashInvestingItemsAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "auth_ref": [] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition", "http://portagebiotech.com/role/Non-controllingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Non-controlling interest", "periodStartLabel": "Non-controlling interest, at beginning", "periodEndLabel": "Non-controlling interest, at ending" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r13", "r81", "r85" ] }, "ifrs-full_NoncontrollingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncontrollingInterestsMember", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/StockOptionReserveDetails" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests [member]" } }, "en": { "role": { "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent." } } }, "auth_ref": [ "r4" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Total non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r17", "r91", "r159" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition", "http://portagebiotech.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "Lease liability - non-current" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r112" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Non-current liabilities [Default Label]" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r18", "r93", "r159" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities" } } }, "auth_ref": [] }, "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotesAndOtherExplanatoryInformationAbstract", "lang": { "en-us": { "role": { "label": "Notes and other explanatory information [abstract]" } } }, "auth_ref": [] }, "ptgef_NotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NotesReceivable", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes receivable" } } }, "auth_ref": [] }, "ptgef_NumberOfInstrumentsOrInterestsIssuedOrIssuables": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuables", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of ordinary shares issued in acquisition" } } }, "auth_ref": [] }, "ptgef_NumberOfOrdinaryShareIssued": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfOrdinaryShareIssued", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of ordinary share issued" } } }, "auth_ref": [] }, "ptgef_NumberOfOutstandingShareOption": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfOutstandingShareOption", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "label": "NumberOfOutstandingShareOption" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options outstanding" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r119", "r121", "r122" ] }, "ptgef_NumberOfPrefundedShareWarrantPurchase": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfPrefundedShareWarrantPurchase", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of Prefunded share warrant purchase" } } }, "auth_ref": [] }, "ptgef_NumberOfPrivateCompanySharesConsistsInSoleAsset": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfPrivateCompanySharesConsistsInSoleAsset", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of private company share consists in sole asset" } } }, "auth_ref": [] }, "ptgef_NumberOfShareIssued": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfShareIssued", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of share issued" } } }, "auth_ref": [] }, "ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1" ], "lang": { "en-us": { "role": { "label": "Exercisable, end of period" } } }, "auth_ref": [] }, "ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1" ], "lang": { "en-us": { "role": { "label": "Expired or forfeited" } } }, "auth_ref": [] }, "ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1" ], "lang": { "en-us": { "role": { "label": "Granted" } } }, "auth_ref": [] }, "ptgef_NumberOfSharesAvailableForAwards": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfSharesAvailableForAwards", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares available for awards" } } }, "auth_ref": [] }, "ptgef_NumberOfSharesAvailableForGranted": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfSharesAvailableForGranted", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares available for granted" } } }, "auth_ref": [] }, "ptgef_NumberOfSharesAvailableForGrants": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfSharesAvailableForGrants", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares available for grants" } } }, "auth_ref": [] }, "ptgef_NumberOfSharesAvailableForOptionGranted": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfSharesAvailableForOptionGranted", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares available for option granted" } } }, "auth_ref": [] }, "ptgef_NumberOfSharesExchanged": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfSharesExchanged", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares exchanged" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesIssued", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issued", "verboseLabel": "Number of shares issued" } }, "en": { "role": { "documentation": "The number of shares issued by the entity." } } }, "auth_ref": [ "r191" ] }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesIssuedAndFullyPaid", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase ordinary shares" } }, "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } } }, "auth_ref": [ "r21" ] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance, shares", "periodEndLabel": "Ending Balance, shares", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r22" ] }, "ptgef_NumberOfSharesPurchased": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfSharesPurchased", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares purchased" } } }, "auth_ref": [] }, "ptgef_NumberOfSharesSold": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfSharesSold", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares sold" } } }, "auth_ref": [] }, "ptgef_NumberOfStockSold": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumberOfStockSold", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of stock sold", "label": "NumberOfStockSold" } } }, "auth_ref": [] }, "ptgef_NumeratorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "NumeratorAbstract", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Numerator (in 000\u2019$)" } } }, "auth_ref": [] }, "ptgef_OCIMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "OCIMember", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "O C I [Member]" } } }, "auth_ref": [] }, "ptgef_OfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "OfferingExpenses", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Offering expenses" } } }, "auth_ref": [] }, "ptgef_OfferingsManagementFeeEqualPercentage": { "xbrltype": "percentItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "OfferingsManagementFeeEqualPercentage", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Offerings management fee equal percentage" } } }, "auth_ref": [] }, "ptgef_OncomerSaugatuckDNAAptamersMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "OncomerSaugatuckDNAAptamersMember", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Oncomer Saugatuck D N A Aptamers [Member]" } } }, "auth_ref": [] }, "ptgef_OptionLifeShareOptions": { "xbrltype": "durationItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "OptionLifeShareOptions", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetails2", "http://portagebiotech.com/role/WarrantLiabilityDetails3" ], "lang": { "en-us": { "role": { "label": "Expected life" } } }, "auth_ref": [] }, "ptgef_OrdinaryNumberOfStockSold": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "OrdinaryNumberOfStockSold", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of stock sold" } } }, "auth_ref": [] }, "ptgef_OrdinarySharesIssuedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "OrdinarySharesIssuedValue", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ordinary shares issued value" } } }, "auth_ref": [] }, "ptgef_OrdinarySharesOutstandingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "OrdinarySharesOutstandingPercentage", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of ordinary shares outstanding" } } }, "auth_ref": [] }, "ptgef_OrdinarySharesPurchase": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "OrdinarySharesPurchase", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ordinary shares purchase" } } }, "auth_ref": [] }, "ptgef_OrdinarySharesValue": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "OrdinarySharesValue", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ordinary shares value" } } }, "auth_ref": [] }, "ptgef_OriginalAnnualTargetsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "OriginalAnnualTargetsPercentage", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Original annual targets percentage" } } }, "auth_ref": [] }, "ifrs-full_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other assets, including equipment, net" } }, "en": { "role": { "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r193" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss)" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "parentTag": "ifrs-full_CurrentPrepayments", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r150" ] }, "ifrs-full_OtherExpenseByNature": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherExpenseByNature", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-accountable expenses", "label": "Other expenses, by nature" } }, "en": { "role": { "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]" } } }, "auth_ref": [ "r31", "r147" ] }, "ifrs-full_OtherFeeAndCommissionExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherFeeAndCommissionExpense", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Incurred Board fees total" } }, "en": { "role": { "documentation": "The amount of fee and commission expense that the entity does not separately disclose in the same statement or note. [Refer: Fee and commission expense]" } } }, "auth_ref": [ "r192" ] }, "ptgef_OtherLossesUnrecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "OtherLossesUnrecognized", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Other losses (unrecognized)" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r183" ] }, "ifrs-full_OtherReserves": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherReserves", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Stock option reserve" } }, "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r151" ] }, "ifrs-full_OtherTangibleOrIntangibleAssetsTransferred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherTangibleOrIntangibleAssetsTransferred", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "lang": { "en-us": { "role": { "label": "Total assets" } }, "en": { "role": { "documentation": "The fair value, at acquisition date, of other tangible or intangible assets (including a business or subsidiary of the acquirer) transferred as consideration in a business combination, that the entity does not separately disclose in the same note. [Refer: Intangible assets other than goodwill; Business combinations [member]; Subsidiaries [member]]" } } }, "auth_ref": [ "r125" ] }, "ptgef_PBIAmendedAndRestated2021EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PBIAmendedAndRestated2021EquityIncentivePlanMember", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2" ], "lang": { "en-us": { "role": { "label": "P B I Amended And Restated 2021 Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Share issuance costs", "label": "Payments for share issue costs" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r202" ] }, "ptgef_PercentageOfIncreasedConvertibleNoteShares": { "xbrltype": "percentItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PercentageOfIncreasedConvertibleNoteShares", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of increased convertible note shares" } } }, "auth_ref": [] }, "ptgef_PercentageOfOrdinarySharesAndPrefundedWarrantsSold": { "xbrltype": "percentItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PercentageOfOrdinarySharesAndPrefundedWarrantsSold", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of ordinary shares and pre-funded warrants sold" } } }, "auth_ref": [] }, "ptgef_PercentageOfOutstandingShares": { "xbrltype": "percentItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PercentageOfOutstandingShares", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of outstanding shares" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfVotingEquityInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PercentageOfVotingEquityInterestsAcquired", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of acquire", "verboseLabel": "Percentage of voting equity interests acquired", "terseLabel": "Interest rate" } }, "en": { "role": { "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r124" ] }, "ptgef_PlacementAgentWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PlacementAgentWarrantMember", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Placement Agent Warrant [Member]" } } }, "auth_ref": [] }, "ptgef_PlacementAgentWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PlacementAgentWarrantsMember", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails", "http://portagebiotech.com/role/WarrantLiabilityDetails3", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityTables" ], "lang": { "en-us": { "role": { "label": "Placement Agent Warrants [Member]" } } }, "auth_ref": [] }, "ptgef_PortageOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PortageOrdinaryShares", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Portage ordinary shares" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r177" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r178" ] }, "ptgef_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PreFundedWarrantsMember", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pre Funded Warrants [Member]" } } }, "auth_ref": [] }, "ptgef_PrefundedWarrantPurchasePrice": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PrefundedWarrantPurchasePrice", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prefunded warrant purchase price" } } }, "auth_ref": [] }, "ptgef_PrepaidExpensesAndOtherReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PrepaidExpensesAndOtherReceivable", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Prepaid expenses and other receivables", "label": "Prepaid Expenses And Other Receivable" } } }, "auth_ref": [] }, "ptgef_PretaxIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PretaxIncomeLoss", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "label": "Pre-tax loss" } } }, "auth_ref": [] }, "ptgef_PretaxLossSubjectToTax": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PretaxLossSubjectToTax", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "label": "Taxable income (loss)" } } }, "auth_ref": [] }, "ptgef_PricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PricePerShare", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Price per share" } } }, "auth_ref": [] }, "ifrs-full_PrincipalPlaceOfBusinessOfAssociate": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PrincipalPlaceOfBusinessOfAssociate", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Principal activity" } }, "en": { "role": { "documentation": "The principal place of business of an associate. [Refer: Principal place of business; Associates [member]]" } } }, "auth_ref": [ "r49", "r53", "r88" ] }, "ptgef_PrivateInvestmentsInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PrivateInvestmentsInterest", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private investment interest" } } }, "auth_ref": [] }, "ptgef_PrivateWarrantSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PrivateWarrantSharesMember", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Warrant Shares [Member]" } } }, "auth_ref": [] }, "ptgef_ProFormaAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ProFormaAdjustments", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pro forma adjustments" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds from warrant" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r202" ] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from offering" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r202" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/EventsAfterBalanceSheetDateDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net proceeds warrants", "verboseLabel": "Proceeds from sale of shares, net of related expenses" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r158" ] }, "ptgef_ProceedsFromRegisteredDirectOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ProceedsFromRegisteredDirectOffering", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Registered Direct Offering" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromSalesOfBiologicalAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromSalesOfBiologicalAssets", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net proceeds", "verboseLabel": "Net proceeds from sale" } }, "en": { "role": { "documentation": "The cash inflow from sales of biological assets. [Refer: Biological assets]" } } }, "auth_ref": [ "r201" ] }, "ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from shares issued under ATM and Committed Purchase Agreement" } } }, "auth_ref": [] }, "ifrs-full_ProfessionalFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfessionalFeesExpense", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated offering expenses" } }, "en": { "role": { "documentation": "The amount of fees paid or payable for professional services." } } }, "auth_ref": [ "r192" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss for period", "verboseLabel": "Net loss for the period" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r2", "r25", "r74", "r78", "r80", "r140", "r142", "r159", "r164" ] }, "ifrs-full_ProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Expenses" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Net loss attributable to:" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToNoncontrollingInterests", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-controlling interest", "label": "Profit (loss), attributable to non-controlling interests" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]" } } }, "auth_ref": [ "r27", "r84" ] }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss", "http://portagebiotech.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Owners of the Company", "verboseLabel": "Net loss attributable to owners of the Company" } }, "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r28" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ptgef_NetLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before benefit (expense) for income taxes", "label": "Profit (loss) before tax" } }, "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r133", "r147", "r148", "r168", "r169" ] }, "ptgef_ProfitLossFromContinuingOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ProfitLossFromContinuingOperation", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Benefit from income taxes" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossFromContinuingOperations", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails1" ], "lang": { "en-us": { "role": { "label": "Loss from operations" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]" } } }, "auth_ref": [ "r25", "r95", "r140", "r142" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Profit (loss) from operating activities" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r156", "r195" ] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of ownership subsidiary" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r50", "r54", "r86" ] }, "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-controlling interest", "label": "Proportion of ownership interests held by non-controlling interests" } }, "en": { "role": { "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests]" } } }, "auth_ref": [ "r83" ] }, "ifrs-full_ProportionOfVotingPowerHeldInAssociate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProportionOfVotingPowerHeldInAssociate", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails" ], "lang": { "en-us": { "role": { "label": "Voting rights held" } }, "en": { "role": { "documentation": "The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]" } } }, "auth_ref": [ "r50", "r54", "r89" ] }, "ifrs-full_ProvisionUsedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProvisionUsedOtherProvisions", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Provision for impairment" } }, "en": { "role": { "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r65" ] }, "ptgef_PublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PublicFloat", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Public float" } } }, "auth_ref": [] }, "ptgef_PurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PurchaseAgreementMember", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase Agreement [Member]" } } }, "auth_ref": [] }, "ptgef_PurchaseOfConvertibleNoteReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PurchaseOfConvertibleNoteReceivable", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of convertible note receivable", "label": "PurchaseOfConvertibleNoteReceivable" } } }, "auth_ref": [] }, "ptgef_PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PurchaseOfNoncontrollingInterestPursuantToShareExchangeAgreement", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/Non-controllingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Purchase of non-controlling interest pursuant to Share Exchange Agreement" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r157" ] }, "ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PurchaseOfSharesIssuedUnderCommittedPurchaseAgreement", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Purchase of shares issued under Committed Purchase Agreement" } } }, "auth_ref": [] }, "ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCosts", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "label": "Purchase of shares issued under Committed Purchase Agreement, net of issue costs, amount" } } }, "auth_ref": [] }, "ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementNetOfIssueCostsShares", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "label": "Purchase of shares issued under Committed Purchase Agreement, net of issue costs, shares" } } }, "auth_ref": [] }, "ptgef_PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PurchaseOfSharesIssuedUnderCommittedPurchaseAgreementShares", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Purchase of shares issued under Committed Purchase Agreement, shares" } } }, "auth_ref": [] }, "ptgef_PurchaseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PurchaseOfWarrants", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Purchase warrants", "label": "PurchaseOfWarrants" } } }, "auth_ref": [] }, "ptgef_PurchasePrice": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PurchasePrice", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase price" } } }, "auth_ref": [] }, "ptgef_PurchasePriceOfPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PurchasePriceOfPerShare", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase price of per share" } } }, "auth_ref": [] }, "ptgef_PurchaseWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "PurchaseWarrants", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase warrants" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r108", "r117", "r122", "r161", "r163", "r209" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "auth_ref": [] }, "ifrs-full_RangesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangesMember", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r108", "r117", "r122", "r161", "r163", "r209" ] }, "ptgef_RecognizedImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "RecognizedImpairment", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Recognized an impairment" } } }, "auth_ref": [] }, "ptgef_ReductionDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ReductionDeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reduction of deferred tax liabilities" } } }, "auth_ref": [] }, "ptgef_RepaymentOfLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "RepaymentOfLeaseLiability", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of lease liability", "label": "RepaymentOfLeaseLiability" } } }, "auth_ref": [] }, "ptgef_RepaymentOfMilestoneObligationAssumedInTarusAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "RepaymentOfMilestoneObligationAssumedInTarusAcquisition", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of milestone obligation assumed in Tarus acquisition", "label": "RepaymentOfMilestoneObligationAssumedInTarusAcquisition" } } }, "auth_ref": [] }, "ptgef_RepaymentOfNotesPayableAssumedInTarusAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "RepaymentOfNotesPayableAssumedInTarusAcquisition", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of notes payable assumed in Tarus acquisition", "label": "RepaymentOfNotesPayableAssumedInTarusAcquisition" } } }, "auth_ref": [] }, "ptgef_ResaleOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ResaleOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Resale of ordinary shares" } } }, "auth_ref": [] }, "ptgef_ResearchAndDevelopmentCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ResearchAndDevelopmentCredit", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "parentTag": "ifrs-full_CurrentPrepayments", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Research & development tax credits" } } }, "auth_ref": [] }, "ptgef_ResearchAndDevelopmentCreditReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ResearchAndDevelopmentCreditReceivables", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research and development credit receivables" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Research and development" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r66" ] }, "ptgef_ReservedForAwardsPreviouslyGrantedShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ReservedForAwardsPreviouslyGrantedShares", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reserved for awards previously granted shares" } } }, "auth_ref": [] }, "ptgef_RestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "RestrictedStockUnitsMember", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails1" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units [Member]" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r151", "r152" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r4", "r149" ] }, "ifrs-full_RevenueFromInterest": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromInterest", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Interest income" } }, "en": { "role": { "documentation": "The amount of income arising from interest." } } }, "auth_ref": [ "r98", "r136", "r145", "r192" ] }, "ifrs-full_ReversalOfImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReversalOfImpairmentLoss", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Impairment of convertible note" } }, "en": { "role": { "documentation": "The amount recognised as an increase of the carrying amount of an asset or cash-generating unit to its recoverable amount when an impairment loss had been previously recognised. [Refer: Impairment loss]" } } }, "auth_ref": [ "r61", "r62" ] }, "ptgef_ReversalsOfImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ReversalsOfImpairmentLoss", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Impairment loss", "label": "ReversalsOfImpairmentLoss" } } }, "auth_ref": [] }, "ptgef_ReverseStockSplitHoldingShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ReverseStockSplitHoldingShares", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Holding shares" } } }, "auth_ref": [] }, "ptgef_RightToUseAssetAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "RightToUseAssetAcquired", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right to use asset acquired" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Right to use asset" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r111", "r113" ] }, "ptgef_SaleOfWarrantPercentage": { "xbrltype": "percentItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SaleOfWarrantPercentage", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of warrant percentage" } } }, "auth_ref": [] }, "ifrs-full_SaleOrIssueOfTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SaleOrIssueOfTreasuryShares", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "label": "Shares issued or accrued for services, amount" } }, "en": { "role": { "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]" } } }, "auth_ref": [ "r191" ] }, "ptgef_SalvaRxGroupPlcMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SalvaRxGroupPlcMember", "presentation": [ "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Salva Rx Group Plc [Member]" } } }, "auth_ref": [] }, "ptgef_SalvaRxMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SalvaRxMember", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Salva Rx [Member]" } } }, "auth_ref": [] }, "ptgef_SaugatuckAndSubsidiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SaugatuckAndSubsidiaryMember", "presentation": [ "http://portagebiotech.com/role/Non-controllingInterestDetails" ], "lang": { "en-us": { "role": { "label": "Saugatuck And Subsidiary [Member]" } } }, "auth_ref": [] }, "ptgef_SaugatuckMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SaugatuckMember", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Saugatuck [Member]" } } }, "auth_ref": [] }, "ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ScheduleOfAntiDilutiveEffectTableTextBlock", "presentation": [ "http://portagebiotech.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of anti-dilutive share" } } }, "auth_ref": [] }, "ptgef_ScheduleOfEarningsPerShareTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ScheduleOfEarningsPerShareTableTextBlock", "presentation": [ "http://portagebiotech.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of basic and diluted EPS" } } }, "auth_ref": [] }, "ptgef_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusTables" ], "lang": { "en-us": { "role": { "label": "Schedule of fair value of assets acquired and liabilities assumed" } } }, "auth_ref": [] }, "ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ScheduleOfInProcessResearchAndDevelopmentTableTextBlock", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of in-process research and development" } } }, "auth_ref": [] }, "ptgef_ScheduleOfIncomeTaxTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ScheduleOfIncomeTaxTableTextBlock", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of effective income tax rates" } } }, "auth_ref": [] }, "ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ScheduleOfIncomeTaxesBenefitTableTextBlock", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of income tax benefit" } } }, "auth_ref": [] }, "ptgef_ScheduleOfNoncontrollingInterestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ScheduleOfNoncontrollingInterestTableTextBlock", "presentation": [ "http://portagebiotech.com/role/Non-controllingInterestTables" ], "lang": { "en-us": { "role": { "label": "Schedule of non controlling interest" } } }, "auth_ref": [] }, "ptgef_ScheduleOfProformaInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ScheduleOfProformaInformationTableTextBlock", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusTables" ], "lang": { "en-us": { "role": { "label": "Schedule of pro forma information" } } }, "auth_ref": [] }, "ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of reconciliation income tax rates" } } }, "auth_ref": [] }, "ptgef_ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of reconciliation of financial statement income (loss)" } } }, "auth_ref": [] }, "ptgef_ScheduleOfWarrantLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ScheduleOfWarrantLiabilityTableTextBlock", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of warrant liability" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r171" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r175" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r174" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r179" ] }, "ifrs-full_SegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SegmentsAxis", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "label": "Segments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r62", "r110", "r140", "r155", "r165" ] }, "ifrs-full_SegmentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SegmentsMember", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "lang": { "en": { "role": { "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used." } } }, "auth_ref": [ "r62", "r110", "r146", "r155", "r165" ] }, "ptgef_SeiesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SeiesBWarrantsMember", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Seies B Warrants [Member]" } } }, "auth_ref": [] }, "ptgef_SeiesCWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SeiesCWarrantsMember", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Seies C Warrants [Member]" } } }, "auth_ref": [] }, "ptgef_SeriesAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SeriesAWarrantsMember", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails1", "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series A Warrants [Member]" } } }, "auth_ref": [] }, "ptgef_SeriesBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SeriesBWarrantsMember", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityTables" ], "lang": { "en-us": { "role": { "label": "Series B Warrants [Member]" } } }, "auth_ref": [] }, "ptgef_SeriesCWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SeriesCWarrantsMember", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityDetails2", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityTables" ], "lang": { "en-us": { "role": { "label": "Series C Warrants [Member]" } } }, "auth_ref": [] }, "ptgef_ServiceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ServiceCosts", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "service costs" } } }, "auth_ref": [] }, "ptgef_SettledInIoxExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SettledInIoxExchange", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails" ], "lang": { "en-us": { "role": { "label": "Settled in iOx exchange" } } }, "auth_ref": [] }, "ptgef_ShareIssuanceCostsUnderAtm": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ShareIssuanceCostsUnderAtm", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share issuance costs under ATM" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Share issuance costs", "label": "Share issue related cost" } }, "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } } }, "auth_ref": [ "r191" ] }, "ptgef_ShareIssuedInIoxExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ShareIssuedInIoxExchange", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "label": "Shares issued in iOx exchange, amount" } } }, "auth_ref": [] }, "ptgef_ShareIssuedToLincolnParkCommittedPurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ShareIssuedToLincolnParkCommittedPurchase", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "label": "Shares issued to Lincoln for commitment fee under Committed Purchase Agreement, amount" } } }, "auth_ref": [] }, "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Share of loss in associate accounted for using equity method" } }, "en": { "role": { "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]" } } }, "auth_ref": [ "r195" ] }, "ptgef_SharePriceFairvalue": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharePriceFairvalue", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetails2", "http://portagebiotech.com/role/WarrantLiabilityDetails3" ], "lang": { "en-us": { "role": { "label": "Share price" } } }, "auth_ref": [] }, "ptgef_SharebasedCompensationExpenseForFinancialStatementPurposesForWhichNoBenefitWasTaken": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharebasedCompensationExpenseForFinancialStatementPurposesForWhichNoBenefitWasTaken", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "label": "Share-based compensation expense for financial statement purposes for which no benefit was taken" } } }, "auth_ref": [] }, "ptgef_SharebasedCompensationExpenseRecognizedForFinancialStatementPurposes": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharebasedCompensationExpenseRecognizedForFinancialStatementPurposes", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Share-based compensation expense recognized for financial statement purposes" } } }, "auth_ref": [] }, "ptgef_ShareholdersEquityAttributableToOwners": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "ShareholdersEquityAttributableToOwners", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shareholders' equity attributable to owners" } } }, "auth_ref": [] }, "ptgef_SharesIssuedInIoxExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedInIoxExchange", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued in iOx exchange" } } }, "auth_ref": [] }, "ptgef_SharesIssuedInIoxExchangeShare": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedInIoxExchangeShare", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issued in iOx exchange, shares", "label": "SharesIssuedInIoxExchangeShare" } } }, "auth_ref": [] }, "ptgef_SharesIssuedInIoxExchangeShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedInIoxExchangeShares", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued in iOx exchange, shares" } } }, "auth_ref": [] }, "ptgef_SharesIssuedInTarusAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedInTarusAcquisition", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued in Tarus acquisition" } } }, "auth_ref": [] }, "ptgef_SharesIssuedInTarusAcquisitionShare": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedInTarusAcquisitionShare", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issued in Tarus acquisition, shares", "label": "SharesIssuedInTarusAcquisitionShare" } } }, "auth_ref": [] }, "ptgef_SharesIssuedInTarusAcquisitionShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedInTarusAcquisitionShares", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued in Tarus acquisition, shares" } } }, "auth_ref": [] }, "ptgef_SharesIssuedInTarusAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedInTarusAcquisitions", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "label": "Shares issued in Tarus acquisition, amount" } } }, "auth_ref": [] }, "ptgef_SharesIssuedOrAccruedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedOrAccruedForServices", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued or accrued for services" } } }, "auth_ref": [] }, "ptgef_SharesIssuedOrAccruedForServicesShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedOrAccruedForServicesShares", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued or accrued for services, shares" } } }, "auth_ref": [] }, "ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreement", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued to Lincoln for commitment fee under Committed Purchase Agreement" } } }, "auth_ref": [] }, "ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShare": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShare", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares issued to Lincoln for commitment fee under Committed Purchase Agreement, shares", "label": "SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShare" } } }, "auth_ref": [] }, "ptgef_SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedToLincolnForCommitmentFeeUnderCommittedPurchaseAgreementShares", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued to Lincoln for commitment fee under Committed Purchase Agreement, shares" } } }, "auth_ref": [] }, "ptgef_SharesIssuedUnderAtm": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedUnderAtm", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued under ATM" } } }, "auth_ref": [] }, "ptgef_SharesIssuedUnderAtmNetOfIssueCosts": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedUnderAtmNetOfIssueCosts", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "label": "Shares issued under ATM, net of issue costs, shares" } } }, "auth_ref": [] }, "ptgef_SharesIssuedUnderAtmNetOfIssueCostsAmount": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedUnderAtmNetOfIssueCostsAmount", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "label": "Shares issued under ATM, net of issue costs" } } }, "auth_ref": [] }, "ptgef_SharesIssuedUnderAtmShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedUnderAtmShares", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued under ATM, shares" } } }, "auth_ref": [] }, "ptgef_SharesIssuedUnderRegisteredDirectOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedUnderRegisteredDirectOffering", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued under Registered Direct Offering" } } }, "auth_ref": [] }, "ptgef_SharesIssuedUnderRegisteredDirectOfferingShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedUnderRegisteredDirectOfferingShares", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued under registered direct offering, shares" } } }, "auth_ref": [] }, "ptgef_SharesIssuedUnderRegisteredDirectPublicOfferingNetOfIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedUnderRegisteredDirectPublicOfferingNetOfIssueCosts", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "label": "Shares issued under Registered Direct Offering, net of issue costs" } } }, "auth_ref": [] }, "ptgef_SharesIssuedUnderRegisteredDirectPublicOfferingNetOfIssueCostsShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SharesIssuedUnderRegisteredDirectPublicOfferingNetOfIssueCostsShares", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "lang": { "en-us": { "role": { "label": "Shares issued under Registered Direct Offering, net of issue costs, shares" } } }, "auth_ref": [] }, "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of shares" } }, "en": { "role": { "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares." } } }, "auth_ref": [ "r23" ] }, "ifrs-full_ShorttermEmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermEmployeeBenefitsExpense", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short term debt" } }, "en": { "role": { "documentation": "The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services." } } }, "auth_ref": [ "r192" ] }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantInvestmentsInAssociatesAxis", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails", "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Associates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r51", "r55", "r102" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r180" ] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails", "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/StockOptionReserveDetails", "http://portagebiotech.com/role/WarrantLiabilityDetails", "http://portagebiotech.com/role/WarrantLiabilityDetails1", "http://portagebiotech.com/role/WarrantLiabilityDetails2", "http://portagebiotech.com/role/WarrantLiabilityDetails3", "http://portagebiotech.com/role/WarrantLiabilityTables" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r4" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "ptgef_StatutoryU.s.IncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "StatutoryU.s.IncomeTaxRate", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Statutory U.S. income tax rate" } } }, "auth_ref": [] }, "ptgef_StimunitySAMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "StimunitySAMember", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails", "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stimunity S A [Member]" } } }, "auth_ref": [] }, "ptgef_StockGranted": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "StockGranted", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock granted" } } }, "auth_ref": [] }, "ptgef_StockIssuedDuringPeriodShareRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "StockIssuedDuringPeriodShareRestrictedStockAwardGross", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares remained available for future awards" } } }, "auth_ref": [] }, "ptgef_StockOptionReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "StockOptionReserve", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "label": "StockOptionReserve" } } }, "auth_ref": [] }, "ptgef_StockOptionReserveMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "StockOptionReserveMember", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/StockOptionReserveDetails" ], "lang": { "en-us": { "role": { "label": "Stock Option Reserve [Member]" } } }, "auth_ref": [] }, "ptgef_StockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "StockOptionsMember", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails1", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock Options [Member]" } } }, "auth_ref": [] }, "ptgef_SupplementalCashFlowInformationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "SupplementalCashFlowInformationsAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "ptgef_TarusAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "TarusAcquisitionMember", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tarus Acquisition [Member]" } } }, "auth_ref": [] }, "ptgef_TarusAdenosineReceptors1Member": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "TarusAdenosineReceptors1Member", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Tarus Adenosine Receptors 1 [Member]" } } }, "auth_ref": [] }, "ptgef_TarusAdenosineReceptors2Member": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "TarusAdenosineReceptors2Member", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Tarus Adenosine Receptors 2 [Member]" } } }, "auth_ref": [] }, "ptgef_TarusAdenosineReceptorsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "TarusAdenosineReceptorsMember", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Tarus Adenosine Receptors [Member]" } } }, "auth_ref": [] }, "ptgef_TarusMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "TarusMember", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Tarus [Member]" } } }, "auth_ref": [] }, "ptgef_TarusTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "TarusTherapeuticsIncMember", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tarus Therapeutics Inc [Member]" } } }, "auth_ref": [] }, "ptgef_TaxDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "TaxDeposits", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "parentTag": "ifrs-full_CurrentPrepayments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Tax deposits" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectFromChangeInTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectFromChangeInTaxRate", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net tax benefit" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]" } } }, "auth_ref": [ "r35" ] }, "ptgef_TaxEffectOfTaxLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "TaxEffectOfTaxLoss", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in the deferred income tax rate", "label": "TaxEffectOfTaxLoss" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfTaxLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectOfTaxLosses", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Income tax benefit" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]" } } }, "auth_ref": [ "r35" ] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "lang": { "en-us": { "role": { "label": "Loss at statutory income tax rate" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r35" ] }, "ptgef_TitleOfIndividualsAxis": { "xbrltype": "stringItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "TitleOfIndividualsAxis", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title Of Individuals [Axis]", "verboseLabel": "TitleOfIndividualsAxis [Axis]" } } }, "auth_ref": [] }, "ptgef_TitleOfIndividualsDomain": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "TitleOfIndividualsDomain", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative", "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Top of range [member]" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r108", "r117", "r122", "r161", "r163", "r209" ] }, "ptgef_TotalCashFeeEqualPercentage": { "xbrltype": "percentItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "TotalCashFeeEqualPercentage", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total cash fee equal percentage" } } }, "auth_ref": [] }, "ptgef_TotalComprehensiveLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "TotalComprehensiveLoss", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails1" ], "lang": { "en-us": { "role": { "label": "Total comprehensive loss for period" } } }, "auth_ref": [] }, "ptgef_TotalCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "TotalCurrentLiabilities", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total current liabilities" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r11" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r9", "r19" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r128" ] }, "ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for transactions that are recognised separately from the acquisition of assets and assumption of liabilities in business combinations. It also represents the standard value for the 'Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination' axis if no other member is used. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r128" ] }, "ifrs-full_TypesOfInvestmentPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfInvestmentPropertyAxis", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Types of investment property [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r192" ] }, "ptgef_UnamortizedOfDeferredCommitmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "UnamortizedOfDeferredCommitmentFee", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unamortized of deferred commitment fee" } } }, "auth_ref": [] }, "ptgef_UnitedStateMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "UnitedStateMember", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "label": "United State [Member]" } } }, "auth_ref": [] }, "ptgef_UnrecognisedConversionOfStimunityConvertibleNoteOfAssociates": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "UnrecognisedConversionOfStimunityConvertibleNoteOfAssociates", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails1" ], "lang": { "en-us": { "role": { "label": "Conversion of Stimunity Convertible Note" } } }, "auth_ref": [] }, "ptgef_UnrecognisedShareOfLossesOfAssociate": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "UnrecognisedShareOfLossesOfAssociate", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateAndConvertibleNoteReceivableDetails1" ], "lang": { "en-us": { "role": { "label": "Share of loss" } } }, "auth_ref": [] }, "ptgef_UnvestedOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "UnvestedOptionsMember", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unvested Options [Member]" } } }, "auth_ref": [] }, "ptgef_UtilizationOfLossNotPreviouslyBenefitted": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "UtilizationOfLossNotPreviouslyBenefitted", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "lang": { "en-us": { "role": { "verboseLabel": "Utilization of losses not previously benefitted", "label": "UtilizationOfLossNotPreviouslyBenefitted" } } }, "auth_ref": [] }, "ptgef_UtilizationOfLossesNotPreviouslyBenefitted": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "UtilizationOfLossesNotPreviouslyBenefitted", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Utilization of losses not previously benefitted" } } }, "auth_ref": [] }, "ptgef_VestedOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "VestedOptionsMember", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vested Options [Member]" } } }, "auth_ref": [] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual base salary" } }, "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r198" ] }, "ptgef_WarrantExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "WarrantExercisePrice", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant exercise price" } } }, "auth_ref": [] }, "ptgef_WarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "WarrantIssued", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant issued" } } }, "auth_ref": [] }, "ifrs-full_WarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WarrantLiability", "crdr": "credit", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds warrant liability", "label": "Warrant liability" } }, "en": { "role": { "documentation": "The amount of warrant liabilities." } } }, "auth_ref": [ "r193" ] }, "ptgef_WarrantLiabilityExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "WarrantLiabilityExercisePrice", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants liability exercise price at beginning", "label": "WarrantLiabilityExercisePrice" } } }, "auth_ref": [] }, "ptgef_WarrantLiabilityNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "WarrantLiabilityNonCurrent", "crdr": "credit", "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Warrant liabilities" } } }, "auth_ref": [] }, "ptgef_WarrantLiabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "WarrantLiabilityTextBlock", "presentation": [ "http://portagebiotech.com/role/WarrantLiability" ], "lang": { "en-us": { "role": { "label": "WARRANT LIABILITY" } } }, "auth_ref": [] }, "ptgef_WarrantsLiabilityFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "WarrantsLiabilityFairValue", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding, fair value at beginning", "label": "WarrantsLiabilityFairValue" } } }, "auth_ref": [] }, "ptgef_WarrantsLiabilityShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "WarrantsLiabilityShares", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding, shares at beginning", "label": "WarrantsLiabilityShares" } } }, "auth_ref": [] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails1" ], "lang": { "en-us": { "role": { "label": "Warrants [member]" } }, "en": { "role": { "documentation": "This member stands for a class of antidilutive instrument representing warrants." } } }, "auth_ref": [ "r199" ] }, "ptgef_WarrantsOutstandingExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "WarrantsOutstandingExercisePrice", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Warrants outstanding exercise price at ending", "label": "WarrantsOutstandingExercisePrice" } } }, "auth_ref": [] }, "ptgef_WarrantsOutstandingFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "WarrantsOutstandingFairValue", "crdr": "debit", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Warrants outstanding, fair value at ending", "label": "WarrantsOutstandingFairValue" } } }, "auth_ref": [] }, "ptgef_WarrantsOutstandingShares": { "xbrltype": "sharesItemType", "nsuri": "http://portagebiotech.com/20231231", "localname": "WarrantsOutstandingShares", "presentation": [ "http://portagebiotech.com/role/WarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Warrants outstanding, shares at ending", "label": "WarrantsOutstandingShares" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r120" ] }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2" ], "lang": { "en-us": { "role": { "verboseLabel": "Expected life", "label": "Weighted average remaining contractual life (in years)" } }, "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r122" ] }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "Share price", "label": "Weighted average share price, share options granted" } }, "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } } }, "auth_ref": [ "r123" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLossParenthetical", "http://portagebiotech.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding, basic", "verboseLabel": "Weighted average number of shares - Basic" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r58" ] }, "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://portagebiotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r188" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2023-03-23" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2023-03-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard", "URIDate": "2023-03-23" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_b&doctype=Standard", "URIDate": "2023-03-23" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2023-03-23" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_e&doctype=Standard", "URIDate": "2023-03-23" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2023-03-23" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2023-03-23" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2023-03-23" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2023-03-23" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_q&doctype=Standard", "URIDate": "2023-03-23" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_r&doctype=Standard", "URIDate": "2023-03-23" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard", "URIDate": "2023-03-23" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard", "URIDate": "2023-03-23" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_vii&doctype=Standard", "URIDate": "2023-03-23" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2023-03-23" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2023-03-23" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2023-03-23" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard", "URIDate": "2023-03-23" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "21", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21_a&doctype=Standard", "URIDate": "2023-03-23" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard", "URIDate": "2023-03-23" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2023-03-23" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2023-03-23" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138&doctype=Standard", "URIDate": "2023-03-23" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard", "URIDate": "2023-03-23" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2023-03-23" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard", "URIDate": "2023-03-23" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2023-03-23" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_vi&doctype=Standard", "URIDate": "2023-03-23" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2023-03-23" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard", "URIDate": "2023-03-23" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2023-03-23" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2023-03-23" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard", "URIDate": "2023-03-23" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2023-03-23" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "126", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126_a&doctype=Standard", "URIDate": "2023-03-23" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "129", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_129_a&doctype=Standard", "URIDate": "2023-03-23" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "130", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_b&doctype=Standard", "URIDate": "2023-03-23" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "134", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_a&doctype=Standard", "URIDate": "2023-03-23" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "135", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_a&doctype=Standard", "URIDate": "2023-03-23" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_c&doctype=Standard", "URIDate": "2023-03-23" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2023-03-23" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "76", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76_g&doctype=Standard", "URIDate": "2023-03-23" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard", "URIDate": "2023-03-23" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "d", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d_v&doctype=Standard", "URIDate": "2023-03-23" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2023-03-23" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard", "URIDate": "2023-03-23" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard", "URIDate": "2023-03-23" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2023-03-23" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2023-03-23" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard", "URIDate": "2023-03-23" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "1", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_1&doctype=Standard", "URIDate": "2023-03-23" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_c&doctype=Standard", "URIDate": "2023-03-23" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_e&doctype=Standard", "URIDate": "2023-03-23" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2023-03-23" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2023-03-23" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "21", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "21", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "21", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B16&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2023-03-23" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2023-03-23" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2023-03-23" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard", "URIDate": "2023-03-23" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS13_g91-99_TI", "URIDate": "2023-03-23" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2023-03-23" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard", "URIDate": "2023-03-23" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_115&doctype=Standard", "URIDate": "2023-03-23" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2023-03-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2023-03-23" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard", "URIDate": "2023-03-23" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2023-03-23" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2023-03-23" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard", "URIDate": "2023-03-23" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard", "URIDate": "2023-03-23" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2023-03-23" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2023-03-23" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "f", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_ii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "f", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_l&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "13C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_13C&doctype=Standard", "URIDate": "2023-03-23" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2023-03-23" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2023-03-23" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2023-03-23" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2023-03-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2023-03-23" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2023-03-23" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2023-03-23" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard", "URIDate": "2023-03-23" }, "r147": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard", "URIDate": "2023-03-23" }, "r148": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r149": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r150": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r151": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r152": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r153": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2023-03-23" }, "r154": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "80", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2023-03-23" }, "r155": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_d&doctype=Standard", "URIDate": "2023-03-23" }, "r156": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2023-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r157": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2023-03-23" }, "r158": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r159": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r160": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard", "URIDate": "2023-03-23" }, "r161": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r162": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "IE60", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE60&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r163": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r164": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2023-03-23" }, "r165": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "96", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_c&doctype=Standard", "URIDate": "2023-03-23" }, "r166": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r167": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "IE72", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_IE72&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r168": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r169": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r170": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r171": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r172": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r174": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r176": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r177": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r178": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r179": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r180": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r181": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r182": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r183": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r184": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r185": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r187": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r188": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r189": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2023-03-23" }, "r191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2023-03-23" }, "r193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard", "URIDate": "2023-03-23" }, "r196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23" }, "r197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81&doctype=Standard", "URIDate": "2023-03-23" }, "r198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard", "URIDate": "2023-03-23" }, "r199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2023-03-23" }, "r200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard", "URIDate": "2023-03-23" }, "r202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2023-03-23" }, "r204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2023-03-23" }, "r205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B64", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "5", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_d&doctype=Standard", "URIDate": "2023-03-23" }, "r209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" } } }